deducibilita

ARTICLES REPOSITORY 2021

ETIOLOGY - PATHOGENESIS - IMMUNOLOGY

Adamo S, et al.
Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection
 
Nabel KG, et al.
Structural basis for continued antibody evasio n by the SARS-CoV-2 receptor binding domain
 
Li X, et al.
SARS-CoV-2 ORF10 suppresses the antiviral innate immune response by degrading MAVS through mitophagy
 
Reynolds CJ, et al.
Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants
 
Le Wang et al
Coronavirus (SARS-CoV-2) causes lung inflammation and injury
ClinicalMicrobiology and Infection,https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(21)00674-1/fulltext
 
Sen K, et al.
Single-Cell Immunogenomic Approach Identified SARS-CoV-2 Protective Immune Signatures in Asymptomatic Direct Contacts of COVID-19 Cases
Front. Immunol. ,
 
Yamaguchi T et al
ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury
 
Wei J,et al.
Anti-spike antibody response to natural SARS-CoV-2 infection in the general population
 
Hsieh WC,, et al.
NK cell receptor and ligand composition influences the clearance of SARS-CoV-2
 
Kukla M et al
Anti-inflammatory adipokines: chemerin, vaspin, omentin concentrations and SARS-CoV-2 outcomes
 
Kim DY et al.
Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients with Coronavirus Disease 2019
 
Kim JM et al.
Viral Shedding among Re-Positive Severe Acute Respiratory Syndrome Coronavirus-2 Positive Individuals in Republic of Korea
 
Witkowski M, et al.
Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells
 
Bräuninger H, et al.
Cardiac SARS-CoV-2 infection is associated with pro-inflammatory transcriptomic alterations within the heart
 
Ravichandran S,e t al.
Systemic and mucosal immune profiling in asymptomatic and symptomatic SARS-CoV-2-infected individuals reveal unlinked immune signatures
Sci Adv., https://www.science.org/doi/10.1126/sciadv.abi6533?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
 
Konik M, et al.
Long-Term SARS-CoV-2 Specific Immunity Is Affected by the Severity of Initial COVID-19 and Patient Age
 
Liu N, Jiang C, et al.
Single-cell analysis of COVID-19, sepsis, and HIV infection reveals hyperinflammatory and immunosuppressive signatures in monocytes
Cell Rep.,
https://www.cell.com/cell-reports/fulltext/S2211-1247(21)01253-5?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124721012535%3Fshowall%3Dtrue
 
Ligotti ME, et al.
Immunopathology and Immunosenescence, the Immunological Key Words of Severe COVID-19. Is There a Role for Stem Cell Transplantation?
 
Ward JD, et al.
Indeterminate QuantiFERON Gold Plus Results Reveal Deficient Interferon Gamma Responses in Severely Ill COVID-19 Patients
 
Khan A, et al.
Virus-induced senescence is driver and therapeutic target in COVID-19.
 
Chang ES, et al.
New-onset IgG autoantibodies in hospitalized patients with COVID-19
 
Niessl J, et al.
Identification of resident memory CD8+ T cells with functional specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue
 
Lili Ren et al
Dynamics of the Upper Respiratory Tract Microbiota and its Association with Mortality in COVID-19
 American Journal of Respiratory and Critical Care Medicine, https://www.atsjournals.org/doi/pdf/10.1164/rccm.202103-0814OC
 
Holmes E.C. et al.
The origins of SARS-CoV-2: A critical review
 
COVID-19 Host genetic initiative
Mapping the human genetic architecture of COVID-19
 
Vanderbeke L et al
Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity
Nature, July 2021 ; DOI: 10.1038/s41467-021-24360-w
 
Breton G et al
Persistent Cellular Immunity to SARS-CoV-2 Infection
BioRXiv, April 2021 ;  DOI: 10.1084/jem.20202515
 
Jung JH et al
SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells
Nature, June 2021; DOI: 10.1038/s41467-021-24377-1
 
Bloom JD
Recovery of deleted deep sequencing data sheds more light on the early Wuhan SARS-CoV-2 epidemic
bioRXiv – preprint, June 2021; doi.org/10.1101/2021.06.18.449051
 
Lei Y et al
SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2
Circulation, December 2020 ; DOI: 10.1101/2020.12.04.409144
 
Scheid JF et al
B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV
Cell, june 2021; DOI: 10.1016/j.cell.2021.04.032
 
Zhou H et al
Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses
 
Turner JS et al
SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
Nature, May 2021; DOI: 10.21203/rs.3.rs-132821/v1
 
Liu Y et al
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
 
Callaway E et al
Coronavirus variants get Greek names — but will scientists use them?
 
World Health Organization
Tracking SARS-CoV-2 variants
 
 Low JS et al
Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2
Science, May 2021; DOI: 10.1126/science.abg8985
 
Series from The Lancet journals
COVID-19: Pathophysiology of Acute Disease
 
Osuchowski MF et al
The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity
 
DeMerle K et al
Precision Medicine for COVID-19 Phenotype Anarchy or Promise Realized?
JAMA, May 2021; doi:10.1001/jama.2021.5248
 
Papayanni P et al
Vaccinated and convalescent donor-derived SARS-CoV-2-specific T cells as adoptive immunotherapy for high-risk COVID-19 patients
CID, April 2021; DOI: 10.1093/cid/ciab371
 
Ravindra NG et al
Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium identifies target cells, alterations in gene expression, and cell state changes
Plos One, March 2021 ; doi.org/10.1371/journal.pbio.3001143
 
Choe H et al
How SARS-CoV-2 first adapted in humans
Science, April 2021 ; DOI: 10.1126/science.abi4711
 
Riou C et al
Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and Tuberculosis co-infection
The Journal of Clinical Investigation, May 2021; doi.org/10.1172/JCI149125
 
Ghai RR et al
Animal Reservoirs and Hosts for Emerging Alphacoronaviruses and Betacoronaviruses
Emerging Infectious Diseases, February 2021; DOI: 10.3201/eid2704.203945
 
Attaway AH et al
Severe covid-19 pneumonia: pathogenesis and clinical management
BMJ, March 2021; doi.org/10.1136/bmj.n436
 
Sokal A et al
Maturation and persistence of the anti-SARS-CoV-2 memory B cell response
 
Schultze JL et al
COVID-19 and the human innate immune system
 
Combes AJ et al
Global absence and targeting of protectiveimmune states in severe COVID-19
Science, January 2021; doi.org/10.1038/s41586-021-03234-7
 
Gaebler C et al
Evolution of antibody immunity to SARS-CoV-2
Nature, January 2021 ; doi.org/10.1038/s41586-021-03207-w
 
EPIDEMIOLOGY

Lewis, H.C.; et al.

SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of standardized seroprevalence studies, from January 2020 to December 2021
 
Scozzari G et al.
Prevalence, Persistence, and Factors Associated with SARS-CoV-2 IgG Seropositivity in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital in Northern Italy
 
Baker MA et al.;
Rapid control of hospital-based SARS-CoV-2 Omicron clusters through daily testing and universal use of N95 respirators
Clinical Infectious Diseases,
 
Konig S. et al.;
A Comparative Analysis of In-Hospital Mortality per Disease Groups in Germany Before and During the COVID-19 Pandemic From 2016 to 2020
JAMA,
 
Chaguza C. et al.
NOT PEER REVIEWED
Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons
medRxiv preprint
 
How well can Omicron evade immunity from COVID vaccines?
 
Murray CJL.
COVID-19 will continue but the end of the pandemic is near
 
Sood N et al.                                       
Seroprevalence of Antibodies Specific to Receptor Binding Domain of SARS-CoV-2 and Vaccination Coverage Among Adults in Los Angeles County, April 2021: The LA Pandemic Surveillance Cohort Study
 
Henry NJ et al.
Variation in excess all-cause mortality by age, sex, and province during the first wave of the COVID-19 pandemic in Italy
Scientific Reports,
 
De Nadai et al.
The impact of control and mitigation strategies during the second wave of coronavirus infections in Spain and Italy
 
European Centre for Disease Prevention and Control
Guidance on quarantine of close contacts to COVID-19 cases and isolation of COVID-19 cases, in the current epidemiological situation, 7 January 2022
 
O. M. Manda S., et al.
A Spatial Analysis of COVID-19 in African Countries:Evaluating the Effects of Socio-Economic Vulnerabilitiesand Neighbouring
International Journal of Environmental Research and Public Health, file:///C:/Users/00122705/Downloads/ijerph-18-10783-v2.pdf
 
Nichols G.L., et al.
Coronavirus seasonality, respiratoryinfections and weather
 
Acosta AM et al.
Racial and Ethnic Disparities in Rates of COVID-19–Associated Hospitalization, Intensive Care Unit Admission, and In-Hospital Death in the United States From March 2020 to February 2021
 
Gianino M.M., et al.
Evaluation of the Strategies to Control COVID-19 Pandemic in Four European Countries
 
Sex-differences in COVID-19 associated excess mortality is not exceptional for the COVID-19 pandemic
 
Brosseau LM et al
SARS-CoV-2 Dose, Infection, and Disease Outcomes for COVID-19 – A Review
Clinical Infectious Diseases,
 
Kossi A. et al.                                                                                       
A model of COVID-19 pandemic evolution in African countries
Scientific African,
 
Deng X et al
Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed Patients
 
Choowe Muzymba
Global Heath Reserch and Policy
Local characterization of the COVID-19 response: the case of a lockdown in Lusaka, Zambia
 
Keehner J. et al.
Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated  Health System Workforce
 
Kofman A et al
Potential COVID-19 Endgame Scenarios Eradication, Elimination, Cohabitation, or Conflagration?
JAMA, July 2021 ; doi:10.1001/jama.2021.11042
 
Dorigatti I et al
SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo’
 
Chu VT et al
Household Transmission of SARS-CoV-2 from Children and Adolescents
NEJM, July 2021 ; DOI: 10.1056/NEJMc2031915
 
Buckee C et al
Thinking clearly about social aspects of infectious disease transmission
 
Woolf SH et al
Effect of the covid-19 pandemic in 2020 on life expectancy across populations in the USA and other high income countries: simulations of provisional mortality data
BMJ, June 2021; DOI: 10.1136/bmj.n1343
 
Althoff KN et al
Antibodies to SARS-CoV-2 in All of Us Research Program Participants, January 2-March 18, 2020
CID, June 2021; DOI: 10.1093/cid/ciab519
 
Food and Drug Administration
Antibody Testing Is Not Currently Recommended to Assess Immunity After COVID-19 Vaccination: FDA Safety Communication
 
Xin H et al.
The incubation period distribution of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis
CID, June 2021 ; DOI: 10.1093/cid/ciab501
 
Salyer SJ et al
The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study
The Lancet, April 2021; DOI: 10.1016/S0140-6736(21)00632-2
 
Wymant C et al
The epidemiological impact of the NHS COVID-19 App
 
Vivier E et al
Specific exposure of ICU staff to SARS-CoV-2 seropositivity: a wide seroprevalence study in a French city-center hospital
Annals of Intensive Care, May 2021; doi.org/10.1186/s13613-021-00868-8
 
Hamilton WL et al
Applying prospective genomic surveillance to support investigation of hospital-onset COVID-19
 
Lee LYW et al
SARS-CoV-2 infectivity by viral load, S gene variants and demographic factors and the utility of lateral flow devices to prevent transmission
CID, April 2021; doi.org/10.1101/2021.03.31.21254687
 
Paul Sax
Some Colleges Require COVID-19 Vaccination — Why Don’t They All?
 
Babak D et al
Should masks be worn outdoors?
BMJ, April 2021 ; doi.org/10.1136/bmj.n1036
 
Barsky BA et al
Vaccination plus Decarceration — Stopping Covid-19 in Jails and Prisons
NEJM,  March 2021 ;  DOI: 10.1056/NEJMp2100609
 
Bhuyan A et al
Experts criticise India's complacency over COVID-19
 
Taylor L
‘We are being ignored’: Brazil’s researchers blame anti-science government for devastating COVID surge
 
Domingo P et al.
Not all COVID-19 pandemic waves are alike
Clinical Microbiology and Infection, April 2021; doi.org/10.1016/j.cmi.2021.04.005
A proactive approach to fight SARS-CoV-2 in Germany and Europe
 
Preprint – not peer reviewed, January 2021;
 
Chan VW et al
Transmission of Severe Acute Respiratory Syndrome Coronavirus 1 and Severe Acute Respiratory Syndrome Coronavirus 2 During Aerosol-Generating Procedures in Critical Care A Systematic Review and Meta-Analysis of Observational Studies
Critical Care Medicine, March 2021; doi: 10.1097/CCM.0000000000004965
 
Cassone A et al
Can reasoned mass testing impact covid-19 outcomes in wide community contexts? An evidence-based opinion
Pathogens and Global Health, July 2020; DOI: 10.21203/rs.3.rs-39944/v1
 
Van der Hurk K et al
Low awareness of past SARS-CoV-2 infection in healthy plasma donors
Cell Reports Medicine, March 2021; doi: 10.1016/j.xcrm.2021.100222
 
Hashan MR et al
Epidemiology and clinical features of COVID-19 outbreaks in aged care facilities: A systematic review and meta-analysis
EClinicalMedicine, March 2021; doi.org/10.1016/j.eclinm.2021.100771
 
Wilmes P et al
SARS-CoV-2 transmission risk from asymptomatic carriers: Results from a mass screening programme in Luxembourg
The Lancet, February 2021; doi.org/10.1016/j.lanepe.2021.100056
 
Murray CJL et al
The Potential Future of the COVID-19 Pandemic Will SARS-CoV-2 Become a Recurrent Seasonal Infection?
JAMA, March 2021 ; doi:10.1001/jama.2021.2828
 
Klein H et al
Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infections. A cohort study in Israeli patients
 
Tan BI et al
Prevalence and Outcomes of SARS-CoV-2 Infection Among Migrant Workers in Singapore
JAMA, February 2021 ;  doi:10.1001/jama.2020.24071
 
Steel K et al
Coronavirus (COVID-19) Infection Survey: characteristics of people testing positive for COVID-19 in England, 27 January 2021
Office for National Statistics.
 
Ren R et al
Asymptomatic SARS-CoV-2 Infections Among Persons Entering China From April 16 to October 12, 2020
JAMA, Febrary 2021 ; doi:10.1001/jama.2020.23942
 
Crane MA et al
Change in Reported Adherence to Nonpharmaceutical Interventions During the COVID-19 Pandemic, April-November 2020
JAMA, January 2021; doi:10.1001/jama.2021.0286
 
Oran DP et al
The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review
Annals of Internal Medicine, January 2021; DOI: 10.7326/M20-6976
 
European Centers for Disease Prevention and Control
Updated rapid risk assessment from ECDC on the risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA – first update
 
Kim MC et al
Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19
NEJM, January 2021; DOI: 10.1056/NEJMc2027040
 
Wang H et al
Performance of Nucleic Acid Amplification Tests for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Prospectively Pooled Specimens
Emerging Infectious Diseases, Volume 27, Number 1—January 2021; DOI: 10.3201/eid2701.203379
 
Li F et al
Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study
The Lancet, 18 January 2021; doi.org/10.1016/S1473-3099(20)30981-6
 
Ranzani OT et al                                                                                                                                     
Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data
The Lancet, 15 January 2021; doi.org/10.1016/S2213-2600(20)30560-9
 
Alteri C et al
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy
Nature, 19  January 2021; doi.org/10.1038/s41467-020-20688-x
 
Holler JG et al
First wave of COVID-19 hospital admissions in Denmark: a Nationwide population-based cohort study
BMC Infectious Diseases, 9 January 2021 ; doi: 10.1186/s12879-020-05717-w
 
Gianotti R et al
COVID‐19 related dermatosis in November 2019. Could this case be Italy’s patient zero?
British Journal of Dermatology, 7 January 2021; doi.org/10.1111/bjd.19804
 
Harrington D et al                                                                       
Confirmed Reinfection with SARS-CoV-2 Variant VOC-202012/01
Clinical Infectious Diseases, 9 January 2021; doi.org/10.1093/cid/ciab014

TRANSMISSION

Ma, Q.; et al.
Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis A Systematic Review and Meta-analysis
                      
Aregu, M.B.; et al.
Safe water supply challenges for hand hygiene in the prevention of COVID-19 in Southern Nations, Nationalities, and People's Region (SNNPR), Ethiopia
Heliyon,
 
Behzadinasab S., et al.
SARS-CoV-2 virus transfers to skin through contact with contaminated solids
 
Bae S et al.
Dynamics of Viral Shedding and Symptoms in Patients with Asymptomatic or Mild COVID-19
 
European Centre for Disease Prevention and Control
Contact tracing in the European Union: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases – fourth update, 28 October 2021
 
Yang Ge MS, et al.
COVID-19 Transmission Dynamics Among Close Contacts of Index Patients With COVID-19 A Population-Based Cohort Study in Zhejiang Province, China
 
Adenaiye OO, et al.
Infectious SARS-CoV-2 in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection
Clinical Infectious Diseases,
 
Maogui H. et al.
Risk of SARS-CoV-2 Transmission among Air Passengers in China
 
Lee JH, et al.
Effectiveness of portable air filtration on reducing indoor aerosol transmission: preclinical observational trials.
J Hosp Infect,
 
Jung J. et al
Clustering and multiple-spreading events of nosocomial severe acute respiratory syndrome coronavirus 2 infection
 
Cevik M et al
Networks of SARS-CoV-2 transmission
Science, July 2021 ; DOI: 10.1126/science.abg0842
 
Muyldermans A et al
SARS-CoV-2 RNA and antibodies in tear fluid
BMJ Open Ophtalmology, April 2021; DOI: 10.1136/bmjophth-2021-000733
 
Karan A et al
The Risk of SARS-CoV-2 Transmission from Patients with Undiagnosed Covid-19 to Roommates in a Large Academic Medical Center
 
Chan VW et al                                                                
Transmission of Severe Acute Respiratory Syndrome Coronavirus 1 and Severe Acute Respiratory Syndrome Coronavirus 2 During Aerosol-Generating Procedures in Critical Care: A Systematic Review and Meta-Analysis of Observational Studies
Critical Care Medicine, July 2021; DOI: 10.1097/CCM.0000000000004965
 
Xiao X et al
Animal sales from Wuhan wet markets immediately prior to the COVID-19 pandemic
Scientific Reports, June 2021 ; doi.org/10.1038/s41598-021-91470-2
 
Razani N et al
Clarification regarding Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses, a Systematic Review
The Journal of Infectious Diseases, June 2021; DOI: 10.1093/infdis/jiab298
 
Jones TC et al
Estimating infectiousness throughout SARS-CoV-2 infection course
Science, May 2021 ; DOI: 10.1126/science.abi5273
 
Jones L et al
Transmission of SARS-CoV-2 on a Patient Transport Van
Clinical Infectious Diseases, April 2021; doi.org/10.1093/cid/ciab347
 
Qiu X et al
The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission—a living systematic review
Clinical Microbiology and Infection, April 2021; DOI: 10.1016/j.cmi.2021.01.011
 
Schuit M et al.
The stability of an isolate of the SARS-CoV-2 B.1.1.7 lineage in aerosols is similar to three earlier isolates
The Journal of Infectious Diseases, April 2021; DOI: 10.1093/infdis/jiab171
 
Park M et al
Determining the communicable period of SARS-CoV-2: A rapid review of the literature, March to September 2020
Eurosurveillance, December 2020; doi.org/10.2807/1560-7917.ES.2021.26.14.2001506
 
Rasmussen AL et al
SARS-CoV-2 transmission without symptoms
Science, March 2021 ; DOI: 10.1126/science.abf9569
 
Schumm MA et al
Filtering Facepiece Respirator (N95 Respirator) Reprocessing: A Systematic Review
JAMA, March 2021; doi:10.1001/jama.2021.2531
 
De Vries RD et al
Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets
Science, February 2021; DOI: 10.1126/science.abf4896
 
Rebeiro PF et al
The Impact of State Mask-Wearing Requirements on the Growth of COVID-19 Cases in the United States
Clinical Infectious Diseases, February 2021 ; doi.org/10.1093/cid/ciab101
 
Qiu X et al
Defining the role of asymptomatic and pre-symptomatic SARS-CoV-2 transmission – a living systematic review
Clinical Microbiology and Infection, OCTOBER 2020; doi.org/10.1101/2020.09.01.20135194
 
Priesemann V et al
An action plan for pan-European defence against new SARS-CoV-2 variants
The Lancet, January 2021; doi.org/10.1016/S0140-6736(21)00150-1
 
Samet JM et al
Airborne Transmission of SARS-CoV-2: What We Know
Clinical Infectious Diseases, January 2021 ; DOI: 10.1093/cid/ciab039
 
Delikhoon M et al
Modes of Transmission of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) and Factors Influencing on the Airborne Transmission: A Review
International Journal fo Environmental Research and Public Health, 6 January 2021;  doi.org/10.3390/ijerph18020395
 
Meyerowitz EA et al
A defense of the classical model of transmission of respiratory pathogens
ClinicalInfectiousDiseases, January 2021 ; doi.org/10.1093/cid/ciab016
 
PREVENTION - PUBLIC HEALTH
 
Dheda, K.; et al.
A position statement and practical guide to the use of particulate filtering facepiece respirators (N95, FFP2, or equivalent) for South African health workers exposed to respiratory pathogens including Mycobacterium tuberculosis and SARS-CoV-2
Afr J Thorac Crit Care Med,
 
Yang B et al.
Universal community nucleic acid testing for COVID-19 in Hong Kong reveals insights into transmission dynamics: a cross-sectional and modelling study
Clinical Infectious Diseases,
 
McNamara L. A. et al.
Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data
 
Lalwani P, et al.
High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort
The Lancet Global Health,
 
Motta FC, et al.
Assessment of Simulated Surveillance Testing and Quarantine in a SARS-CoV-2–Vaccinated Population of Students on a University Campus
 
Revollo B et al.
Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial
Lancet Infectious Diseases,
 
Seung-Ji Kng et al.
Successful control of COVID-19 outbreak through tracing, testing, and isolation: Lessons learned from the outbreak control efforts made in a metropolitan city of South Korea
Journal of Infection and Public Health,
 
 Kathy Leung  1 , Joseph T Wu  2 , Gabriel M Leung
Effects of adjusting public health, travel, and social measures during the roll-out of COVID-19 vaccination: a modelling study
Lancet Public Health,
 
Kiang MV et al
Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation study
The Lancet, July 2021 ; doi.org/10.1016/S1473-3099(21)00134-1
 
Gostin LO et al
Mandatory SARS-CoV-2 Vaccinations in K-12 Schools, Colleges/Universities, and Businesses
JAMA, June 2021; doi:10.1001/jama.2021.9342
 
Talbot TR et al
COVID-19 Vaccination of Health Care Personnel as a Condition of Employment
A Logical Addition to Institutional Safety Programs
JAMA, June 2021 ;  DOI: 10.1001/jama.2021.8901
 
Folgueira MD et al
Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19
 
Patel MD et al
Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality
JAMA, June 2021; doi:10.1001/jamanetworkopen.2021.10782
 
Chia WN et al
Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study
 
Wilson N et al
Estimating the impact of control measures to prevent outbreaks of COVID-19 associated with air travel into a COVID-19-free country
Scientific Report, May 2021 ; doi.org/10.1038/s41598-021-89807-y
Llaydon DJ et al
 
Modelling the impact of the tier system on SARS-CoV-2 transmission in the UK between the first and second national lockdowns
BMJ Open , April 2021; doi: 10.1136/bmjopen-2021-050346
 
Somekh I et al
Comparison of COVID-19 Incidence Rates Before and After School Reopening in Israel
JAMA, April 2021; doi:10.1001/jamanetworkopen.2021.7105
 
Bartoszko JJ et al
Prophylaxis against COVID-19: living systematic review and meta-analysis
BMJ, April 2021; doi.org/10.1136/bmj.n949
 
Sickbert-Bennett EE et al
Fitted Filtration Efficiency of Double Masking During the COVID-19 Pandemic
JAMA, April 2021; doi:10.1001/jamainternmed.2021.2033
 
Ji L et al
Disinfection spreads antimicrobial resistance
Science, 29 January 2021 ;  DOI: 10.1126/science.abg4380
 
Lewis D
COVID-19 rarely spreads through surfaces. So why are we still deep cleaning?
Nature, 29 January 2021; doi.org/10.1038/d41586-021-00251-4
 
Smit M et al
Prophylaxis for COVID-19: a systematic review
Clinical Microbiology and Infection, 18 January; doi: 10.1016/j.cmi.2021.01.013
 
CLINICAL FEATURES AND MORTALITY
 
C. Venter et al.
Erythrocyte, Platelet, Serum Ferritin, and P-Selectin Pathophysiology Implicated in Severe Hypercoagulation and Vascular Complications in COVID-19
Int J Mol Sci, November 2020; doi: 10.3390/ijms21218234
 
F. De Maio et al.
Improved gut microbiota features after the resolution of SARS‑CoV‑2 infection
Gut Pathogens, October 2021; doi.org/10.1186/s13099-021-00459-9
 
D.H. Coelhoet al.                       
Decreasing Incidence of Chemosensory Changes by COVID-19 Variant
Otolaryngol. Head Neck Surg., May 2022; doi: 10.1177/01945998221097656.
 
Zazhytska et al.
Non-cell-autonomous disruption of nuclear architecture as a potential cause of COVID-19-induced anosmia
Cell Press, February 2022; doi.org/10.1016/j.cell.2022.01.024
 
A. Natarajan et al.
Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection
Med, June 2022 ; doi.org/10.1016/j.medj.2022.04.001
 
I.Katsoularis et al.
Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study
 
S. Tsalamandris et al.
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
European Cardiology Review, 2019; doi.org/10.15420/ecr.2018.33.1
 
Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022
MMWR,April 2022;  doi: 10.15585/mmwr.mm7114e1
 
Inflammatory cytokines and cardiac arrhythmias: the lesson from COVID-19
Nat Rev Immunol. 2022; doi: 10.1038/s41577-022-00714-3
 
Zazhytska M et al
Non-cell-autonomous disruption of nuclear architecture as a potential cause of COVID-19-induced anosmia
 
Gwenaëlle Douaud et al.
SARS-CoV-2 is associated with changes in brain structure in UK Biobank
 
Hassler L et al
Potential SARS-CoV-2 kidney infection and paths to injury
 
Xie Y et al
Risks of mental health outcomes in people with covid-19: cohort study
 
Petersen et al.
Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme
European Heart Journal,
 
Paolo Boscolo Rizzo et al.
COVID-19-related Smell and Taste Impairment with Widespread Diffusion of SARS-CoV-2 Omicron Variant
 
Wadman M et al
A rampage through the body
 
Tegan K Boehmer
Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data - United States, March 2020-January 2021
 
Jansen J et al
SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids
 
Belay ED et al.
Multisystem Inflammatory Syndrome in Adults after SARS-CoV-2 infection and COVID-19 vaccination
 
Satterfield BA et al
Cardiac involvement in the long-term implications of COVID-19
 
 Batil A et al
Brain MRI in SARS-CoV-2 pneumonia patients with newly developed neurological manifestations suggestive of brain involvement
 
Fiore G et al
Case report of cardiogenic shock in COVID-19 myocarditis: peculiarities on diagnosis, histology, and treatment
European Heart Journal – Case reports,
 
Hendrickson KW et al                                             
The Epidemiology of Acute Respiratory Distress Syndrome Before and After Coronavirus Disease 2019
 
Banoei MM et al
Machine-learning-based COVID-19 mortality prediction model and identification of patients at low and high risk of dying
 
Boehmer TK, et al.
Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data — United States, March 2020–January 2021
Morbidity and Mortality Weekly Report,
 
Iroungou BA et al.                     
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study
 
Lui L et al.
Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality: A systematic review, meta-analysis and call for action
 EClinical Medicine, https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00391-6/fulltext
 
Patel P et al.
Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults
A Systematic Review
 
Deana C et al
Pericardial Cytokine “Storm” in a COVID-19 Patient: the Confirmation of a Hypothesis
 
Wei EK et al
Nine Lessons Learned From the COVID-19 Pandemic for Improving Hospital Care and Health Care Delivery
JAMA, July 2021 ; doi:10.1001/jamainternmed.2021.4237
 
Jassat W et al
Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study
 
Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study
 
Aschman T et al
Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died
JAMA, June 2021 ; doi:10.1001/jamaneurol.2021.2004
 
Perlis RH et al
Factors Associated With Self-reported Symptoms of Depression Among Adults With and Without a Previous COVID-19 Diagnosis
JAMA, June 2021 ; doi:10.1001/jamanetworkopen.2021.16612
 
Fahmy O et al
Is Microthrombosis the Main Pathology in Coronavirus Disease 2019 Severity?—A Systematic Review of the Postmortem Pathologic Findings
Critical Care Explorations, May 2021; DOI: 10.1097/CCE.0000000000000427
 
Docherty AB et al
Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK
 
Sherry HYC et al
Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19—A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium
JAMA, May 2021; doi:10.1001/jamanetworkopen.2021.12131
 
Davogustto GE et al
Characteristics Associated With Multisystem Inflammatory Syndrome Among Adults With SARS-CoV-2 Infection
JAMA, May 2021; doi:10.1001/jamanetworkopen.2021.10323
 
Roth G et al
Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic
JAMA, May 2021; doi:10.1001/jamanetworkopen.2021.8828
 
Gao M et al
Associations between BMI and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study
 
Wiley Z et al
Racial and Ethnic Differences and Clinical Outcomes of COVID-19 Patients Presenting to the Emergency Department
Clinical Infectious Diseases, April 2021; doi.org/10.1093/cid/ciab290
 
Roubinian NH et al
Incidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California
JAMA, April 2021, doi:10.1001/jamainternmed.2021.0488
 
Tan BK et al
Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis
Thorax , February 2021 ; doi.org/10.1136/thoraxjnl-2020-215383
 
Leal T et al
Gastrointestinal manifestations of COVID-19: results from a European centre
Journal of Gastroenterology and Hepatology, February 2021 ; DOI: 10.1097/MEG.0000000000002152
 
Gallastegui N et al
Pulmonary Embolism Does Not Have an Unusually High Incidence Among Hospitalized COVID19 Patients
Clinical and Applied Thrombosis and Hemostasis, March 2021; doi.org/10.1177/1076029621996471
 
Thompson A et al
Cerebral venous sinus thrombosis associated with COVID-19
BMJ, October 2020 ; DOI: 10.1136/practneurol-2020-002678
 
Hughes C et al
Cerebral Venous Sinus Thrombosis as a Presentation of COVID-19
European Journal of Case Reports in Internal Medicine, April 2020; DOI: 10.12890/2020_001691
 
Tu TM et al
Cerebral Venous Thrombosis in Patients with COVID-19 Infection: a Case Series and Systematic Review
Journal of Stroke and Cerebrovascular Disease, December 2020;
 
Elezkurtaj S et al
Causes of death and comorbidities in hospitalized patients with COVID-19
Scientific Reports, February 2021 ; doi.org/10.1038/s41598-021-82862-5
 
Li JY et al
Clinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID‐19 patients: A multicenter retrospective study
Journal of Thrombosis and Haemostasis, February 2021; doi.org/10.1111/jth.15261
 
Shah P et al
Is Cardiopulmonary Resuscitation Futile in Coronavirus Disease 2019 Patients Experiencing In-Hospital Cardiac Arrest?
Critical Care Medicine, February 2021;  DOI: 10.1097/CCM.0000000000004736
 
Connors JM et al
Thrombosis and COVID-19: Controversies and (Tentative) Conclusions
Clinical Infectious Diseases, February 2021 ; doi.org/10.1093/cid/ciab096
 
Mahase E et al
Covid-19: Sore throat, fatigue, and myalgia are more common with new UK variant
BMJ, January 2021; doi.org/10.1136/bmj.n288 
 
DIAGNOSTIC  
 
Roger S et al.
What is the true place of the SARS-CoV-2 rapid point-of-care antigen test in the hospital setting? Lessons learned from real life
 
Tariq M et al.
Viable Severe Acute Respiratory Syndrome Coronavirus 2 Isolates Exhibit Higher Correlation With Rapid Antigen Assays Than Subgenomic RNA or Genomic RNA
Front Microbiol. ,
 
Beyene GT et al.
Saliva is superior over nasopharyngeal swab for detecting SARS-CoV2 in COVID-19 patients
Sci Rep.,
 
Uddin MKM et al.
Diagnostic Performance of Self-Collected Saliva Versus Nasopharyngeal Swab for the Molecular Detection of SARS-CoV-2 in the Clinical Setting
 
Laferl H et al.
Evaluation of RT-qPCR of mouthwash and buccal swabs for detection of SARS-CoV-2 in children and adults
 
Am J Infect Control.,
 
Turcato G et.
Rapid antigen test to identify COVID-19 infected patients with and without symptoms admitted to the Emergency Department
 
Sauleda et al.
Clinical evaluation of the Procleix SARS-CoV-2 assay, a sensitive, high-throughput test that runs on an automated system
Diagn Microbiol Infect Dis.
 
Winkel B et al.
Screening for SARS-CoV-2 infection in asymptomatic individuals using the Panbio COVID-19 antigen rapid test (Abbott) compared with RT-PCR: a prospective cohort study
BMJ Open ,
 
Cristiano A et al.
Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects
 
Sberna G et al.
Comparison of Allplex™ SARS-CoV-2 Assay, Easy SARS-CoV-2 WE and Lumipulse quantitative SARS-CoV-2 antigen test performance using automated systems for the diagnosis of COVID-19
 
Krempe F et al.
A rapid test recognizing mucosal SARS-CoV-2-specific antibodies distinguishes prodromal from convalescent COVID-19
 
Borges LP et al.
Rapid diagnosis of COVID-19 in the first year of the pandemic: A systematic review
 
Rubin R.
COVID-19 Testing Moves Out of the Clinic and Into the Home
 
Kritikos et al.
Sensitivity of Rapid Antigen Testing and RT-PCR Performed on Nasopharyngeal Swabs versus Saliva Samples in COVID-19 Hospitalized Patients: Results of a Prospective Comparative Trial (RESTART)
 
M. Migueres et al.
Evaluation of two RT-PCR screening assays for identifying SARS-CoV-2 variants
 
Nacher M, et al.
Diagnostic accuracy and acceptability of molecular diagnosis of COVID-19 on saliva samples relative to nasopharyngeal swabs in tropical hospital and extra-hospital contexts: The COVISAL study. 
 
Yokota I et al
A novel strategy for SARS-CoV-2 mass screening with quantitative antigen testing of saliva: a diagnostic accuracy study
 
Ong DSY et al
How to interpret and use COVID-19 serology and immunology tests
Clinical Microbiology and Infection, May 2021; DOI: 10.1016/j.cmi.2021.05.001
 
Jarhult JD et al         
The impact of viremia on organ failure, biomarkers and mortality in a Swedish cohort of critically ill COVID-19 patients
Scientific Reports, March 2021; doi.org/10.1038/s41598-021-86500-y
 
Bauer G et al
The potential significance of high avidity IgG for protective immunity towards SARS-CoV-2
International Journal of Infectious Diseaeses, March 2021; DOI: 10.1016/j.ijid.2021.01.061
 
Van Elslande J et al
Estimated half-life of SARS-CoV-2 anti-spike antibodies more than double the half-life of anti-nucleocapsid antibodies in healthcare workers
Clinical Infectious Diseases, March 2021 ; doi.org/10.1093/cid/ciab219
 
Abbasi J et al
Saliva Tests Comparable With Nasal Swabs for SARS-CoV-2 Detection
JAMA, March 2021; doi:10.1001/jama.2021.1780
 
Carlicchi E et al
Chest-CT mimics of COVID-19 pneumonia-a review article
Emerging Radiology, March 2021; DOI: 10.1007/s10140-021-01919-0
 
Min-Chul K et al
Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19
NEJM, February 2021 ; DOI: 10.1056/NEJMc2027040
 
Folgueira MD et al
Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19
Clinical Microbiology and Infection, February 2021; doi.org/10.1016/j.cmi.2021.02.014
 
May M et al
Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019
Antimicrobial Agents and Chemotherapy, January 2021;  DOI: 10.1128/AAC.02167-20
 
Harvey RA et al
Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection
JAMA, February 2021 ; doi:10.1001/jamainternmed.2021.0366
 
Kevadiya BD et al
Diagnostics for SARS-CoV-2 infections
 
Han MS et al
RT-PCR for SARS-CoV-2: quantitative versus qualitative
 
Manabe Y et al
Self-Collected Oral Fluid Saliva Is Insensitive Compared With Nasal-Oropharyngeal Swabs in the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Outpatients
Open Forum Infectious Diseases, December 2020; doi.org/10.1093/ofid/ofaa648
 
Teo AKJ et al
Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection
Scientific Reports, February 2021; https://doi.org/10.1038/s41598-021-82787-z
 
Sepulcri C et al                                              
The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient – a case study
MedRXiv, January 2021 ; doi.org/10.1101/2021.01.23.21249554
 
Ospedale Pediatrico Bambino Gesù
COMUNICATO STAMPA del 28 gennaio 2021
 
Dacrema A et al
A simple lung ultrasound protocol for the screening of COVID-19 pneumonia in the emergency department
Internal and Emergency Medicine, January 2021; doi: 10.1007/s11739-020-02596-6
 
Fiorentini S et al
First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 2020
The Lancet, January 2021; doi.org/10.1016/ S1473-3099(21)00007-4
 
PROGNOSIS
 
Fonseca W et al.
COVID-19 Modulates Inflammatory and Renal Markers That May Predict Hospital Outcomes among African American Males
 
Epidemiological and Immunological Features of Obesity and SARS-CoV-2
 
Mahamat-Saleh, Y. et al.
Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies
 
Kim L et al.
Clinical Infectious Diseases
Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)
 
Chavez-MacGregor M et al
Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer
 
Mizrahi B et al.
Results of an early second PCR test performed on SARS-CoV-2 positive patients may support risk assessment for severe COVID-19
 
Vishal PS, et al.
Association Between SARS-CoV-2 Cycle Threshold Values and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis
Open Forum in Infect Dis ,
                                        
Mendez R et al
Acute and sustained increase in endothelial biomarkers in COVID-19
 
Espejo-Paeres C et al
Predictors of poor prognosis in healthy, young, individuals with SARS-CoV-2 infections
Clinical Microbiology and Infection,
 
Papamanoli A et al
Association of Serum Ferritin Levels and Methylprednisolone Treatment With Outcomes in Nonintubated Patients With Severe COVID-19 Pneumonia
 
Daix T et al
Journal of Intensive Care
Immature granulocytes can help the diagnosis of pulmonary bacterial infections in patients with severe COVID-19 pneumonia
 
Perez-Garcia F et al.
Age-Adjusted Endothelial Activation and Stress Index for Coronavirus Disease 2019 at Admission Is a Reliable Predictor for 28-Day Mortality in Hospitalized Patients With Coronavirus Disease 2019
 
Sulaiman I et al.
Microbial signatures in the lower airways of mechanically ventilated COVID-19 patients associated with poor clinical outcome
 
Ren-qi Y et al
Development of septic shock and prognostic assessment in critically ill patients with coronavirus disease outside Wuhan, China
World Journal of Emergency Medicine,
 
Reiterer M et al
Hyperglycemia in Acute COVID-19 is Characterized by Insulin Resistance and Adipose Tissue Infectivity by SARS-CoV-2
 
Bailly L et al
Obesity, diabetes, hypertension and severe outcomes among inpatients with COVID-19: a nationwide study
Clinical Microbiology and Infection,
 
Jones A et al
External validation of the 4C mortality score among COVID‑19 patients admitted to hospital in Ontario, Canada: a retrospective study
 
Recalde M et al.
Body mass index and risk of COVID-19 diagnosis, hospitalisation, and death: a cohort study of 2 524 926 Catalans
Journal of Clinical Endocrinology and Metabolism, July 2021; doi.org/10.1210/clinem/dgab546
 
Harrison SL et al.
Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews
European Heart Journal, July 2021;   DOI: 10.1093/ehjqcco/qcab029
 
Lim ZJ et al
A Systematic Review of the Incidence and Outcomes of In-Hospital Cardiac Arrests in Patients With Coronavirus Disease 2019
Critical Care Medicine, March 2021 ; DOI: 10.1097/CCM.0000000000004950
 
Sprung C et al
Reassessing Cardiopulmonary Resuscitation in Hospitalized Patients With Coronavirus Disease 2019
Critical Care Medicine, June 2021; DOI: 10.1097/CCM.0000000000004962
 
Landes SD et al
Risk Factors Associated With COVID-19 Outcomes Among People With Intellectual and Developmental Disabilities Receiving Residential Services
JAMA, June 2021; DOI: 10.1001/jamanetworkopen.2021.12862
 
Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study
 
De Havenon A et al
Characteristics and Outcomes Among US Patients Hospitalized for Ischemic Stroke Before vs During the COVID-19 Pandemic
JAMA, May 2021; doi:10.1001/jamanetworkopen.2021.10314
 
Chou SH et al
Factors Associated With Risk for Care Escalation Among Patients With COVID-19 Receiving Home-Based Hospital Care
Annals of Internal Medicine, May 2021; doi.org/10.7326/M21-0409
 
Bertuzzi AF et al
Impact of active cancer on COVID-19 survival: a matched-analysis on 557 consecutive patients at an Academic Hospital in Lombardy, Italy
British Journal of Cancer – Nature, April 2021; doi.org/10.1038/s41416-021-01396-9
 
Sharov KS
8806 Russian patients demonstrate T cell count as better marker of COVID-19 clinical course severity than SARS-CoV-2 viral load
Scientific Reports, May 2021; DOI: 10.1038/s41598-021-88714-6
 
Wu T et al
Asthma does not influence the severity of COVID-19: a Meta-analysis
Journal of Asthma, April 2021; doi.org/10.1080/02770903.2021.1917603
 
Anderson JL et al
Association of Sociodemographic Factors and Blood Group Type With Risk of COVID-19 in a US Population
JAMA, April 2021; doi:10.1001/jamanetworkopen.2021.7429
 
Mehta HB et al
Risk Factors Associated With SARS-CoV-2 Infections, Hospitalization, and Mortality Among US Nursing Home Residents
JAMA, March 2021; doi:10.1001/jamanetworkopen.2021.6315
 
Frasca D et al
Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients
 
Pranata R et al
Delirium and Mortality in Coronavirus Disease 2019 (COVID-19) - A Systematic Review and Meta-analysis
Archives in Gerontology and Geriatrics, March 2021; DOI: 10.1016/j.archger.2021.104388
 
Saibin W et al
Association between peripheral lymphocyte count and the mortality risk of COVID-19 inpatients
BMC Pulmonary Medicine, February 2021; DOI: 10.1186/s12890-021-01422-9
 
Raschke RA et al
Discriminant Accuracy of the SOFA Score for Determining the Probable Mortality of Patients With COVID-19 Pneumonia Requiring Mechanical Ventilation
JAMA, February 2021; doi:10.1001/jama.2021.1545
 
Benard A et al
Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections
Nature, July 2020; doi.org/10.1101/2020.07.02.184093
 
Gorges RJ et al
Factors Associated With Racial Differences in Deaths Among Nursing Home Residents With COVID-19 Infection in the US
JAMA, Febraury 2021 ; doi:10.1001/jamanetworkopen.2020.37431

TREATMENT

Gottlieb RL et al
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
 
Ospina-Tascon GA et al
Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19 A Randomized Clinical Trial
 
Gupta A et al.
Effect of the Neutralizing SARS-CoV-2 Antibody Sotrovimab in Preventing Progression of COVID-19: A Randomized Clinical Trial
 
Tesmesgen Z et al
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
The Lancet Respiratory Medicine,
 
Menichetti F et al
JAMA Network Open
Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial
 
Axfors C et al
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
BMC InfectiousDiseases
 
Tom J et al
Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial
Critical Care Medicine,
 
Clemency BM et al
Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19
A Randomized Clinical Trial
JAMA Internal Medicine,
 
Aljuhani O et al
Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study
Medicines and Healthcare products Regulatory Agency, UK
 
Regulatory approval of Lagevrio (molnupiravir)
 
Pfizer Press Release
PFIZER’S NOVEL COVID-19 ORAL ANTIVIRAL TREATMENT CANDIDATE REDUCED RISK OF HOSPITALIZATION OR DEATH BY 89% IN INTERIM ANALYSIS OF PHASE 2/3 EPIC-HR STUDY
 
Nature Communications
Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
 
Rosas IO et al
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
Intensive Care Medicine
The Lancet Global Health
 
Reis G et al
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
 
Gupta A et al
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
 
Dougan M et al
A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load 
 
The COVID STEROID 2 Trial Group
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia
JAMA,
 
RECOVERY Collaborative Group
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
 
Izadi Z et al
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
 
Maisonnasse P et al
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
 
Memel ZN et al
Association of Statins and 28-Day Mortality in Patients Hospitalized with SARS CoV-2 Infection
The Journal of Infectious Diseases,
 
Spyropoulos AC et al
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19
The HEP-COVID Randomized Clinical Trial
JAMA Internal Medicine,
 
Dougan M et al
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
 
Al Sulaiman K et al
Ascorbic acid as an adjunctive therapy in critically ill patients with COVID‑19: a propensity score matched study
 
Christie MJ, et al.
Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection
 
O’Brien MP et al.
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
 
Peng J et al
Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis
 
Rosa L et al
Journal of Clinical Medicine
Ambulatory COVID-19 Patients Treated with Lactoferrin as a Supplementary Antiviral Agent: A Preliminary Study
Journal of Clinical Medicine, https://www.mdpi.com/2077-0383/10/18/4276/htm
 
Weinreich DM et al
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
The New England Journal of Medicine,
 
Arpan Acharya et al.
Discovery and evaluation of entry inhibitors for SARS-CoV-2 and its emerging variants.
 
Ader F et al
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
The Lancet Infectious Diseases,
 
Giossi R et al
A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients
 
Vellas C et al
Clinical Microbiology and Infection
Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies
 
Hinks TSC et al
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial
The Lancet, July 2021;  DOI: 10.1016/S2213-2600(21)00263-0
 
Gupta T et al
Hydroxychloroquine in the treatment of coronavirus disease 2019: Rapid updated systematic review and meta-analysis
Rev Med Virol, July 2021 ; DOI: 10.1002/rmv.2276
 
Dougan M et al
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
NEJM, July 2021; DOI: 10.1056/NEJMoa2102685
 
Wang L et al
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
Science, July 2021 ; DOI: 10.1126/science.abh1766
 
Tacquard C et al
Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia
Chest, June 2021 ; doi: 10.1016/j.chest.2021.01.017.
 
Di Castelnuovo A et al
Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study
Front Med, June 2021; DOI: 10.3389/fmed.2021.639970
 
Di Castelnuovo A et al
Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering
Journal of Helathcare Engineering, January 2021; doi.org/10.1101/2021.01.27.21250238
 
Bennett-Guerrero E et al
Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial
Critical Care Med, July 2021;  DOI: 10.1097/CCM.0000000000005066
 
 Di Castelnuovo A et al
Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials
Pathogens and Global Health, June 2021; DOI: 10.1080/20477724.2021.1936818
 
Guimaraes PO et al
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
NEJM, June 2021; DOI: 10.1056/NEJMoa2101643
 
Copin R et al
The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies
 
Rubin R et al
Could Statins Do More Than Lower Cholesterol in Patients With COVID-19?
JAMA, June 2021; doi:10.1001/jama.2021.8201
 
Di Castelnuovo A et al
Research Article Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering
 
Corti D et al
Tackling COVID-19 with neutralizing monoclonal antibodies
Cell, June 2021;  DOI: 10.1016/j.cell.2021.05.005
 
 Lambermont B et al
Outcome Improvement Between the First Two Waves of the Coronavirus Disease 2019 Pandemic in a Single Tertiary-Care Hospital in Belgium
Critical Care Explorations, May 2021; DOI: 10.1097/CCE.0000000000000438
 
Ranjbar K et al
Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial
BMC Infectious Diseases, April 2021; doi.org/10.1186/s12879-021-06045-3
 
Mariette X et al
Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19. A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial
JAMA, May 2021;  doi:10.1001/jamainternmed.2021.2209
 
Ader F et l
An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
Clinical Microbiology and Infection, May 2021; DOI: 10.1016/j.cmi.2021.05.020
 
Medeiros IG et al
A small interfering RNA (siRNA) database for SARS-CoV-2
Scientific Reports, April 2021; doi.org/10.1038/s41598-021-88310-8
 
Ministero della Salute
GESTIONE DOMICILIARE DEI PAZIENTI CON INFEZIONE DA SARS-CoV-2
 
Leentjens J et al
COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year
 
Tleyjeh IM et al
Efficacy and safety of tocilizumab in COVID-19 patients: A living systematic Review and meta-analysis: first update
Clinical Microbiology and Infection, April 2021; doi.org/10.1016/j.cmi.2021.04.019
 
Bafna K et al
Hepatitis C Virus Drugs That Inhibit the SARS-CoV-2 Papain-Like Protease Synergize with Remdesivir to Suppress Viral Replication in Cell Culture
Cell Reports, April 2021; doi.org/10.1016/j.celrep.2021.109133
 
Focosi D et al
Patient-blood management for COVID19 convalescent plasma therapy: should donor-recipient differences in concentration and affinity of neutralizing antibodies drive use?
Clinical Microbiology and Infection, April 2021; doi.org/10.1016/j.cmi.2021.04.003
 
Adarsh B et al
Infectious Diseases Society of America Guidelines on the Treatment and Management ofPatients with COVID-19
InfectiousDiseases Society of America, April 2021 ; DOI: 10.1093/cid/ciaa478
 
Ramakrishnan S et al
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
 
Schjørring OL et al
Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure
NEJM, April 2021; DOI: 10.1056/NEJMoa2032510
 
Kumar RN et al
Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study
Clinical Infectious Diseases, April 2021; doi.org/10.1093/cid/ciab305
 
Ufficio Registri di Monitoraggio AIFA
Monitoraggio Anticorpi Monoclonali per COVID-1
COMMENTO : Dati relativi alla settimana 2 – 8 aprile 2021
(estrazione dati 9 aprile 2021)
 
Gallay L et al
14-Day survival among older adults with severe SARS-Cov2 infection treated with corticosteroid: a cohort study
Clinical Microbiology and Infection, April 2021; doi.org/10.1016/j.cmi.2021.03.021
 
Suter F et al
A SIMPLE, HOME-THERAPY ALGORYTHM TO PREVENT HOSPITALIZATION OF COVID-19 PATIENTS: A RETROSPECTIVE OBSERVATIONAL MATCHED-COHORT STUDY
medRXiv – preprint, not peer reviewed, March 2021; doi.org/10.1101/2021.03.25.21254296
 
European Medicines Agency
EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials
 
Janiaud P et al
Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19 A Systematic Review and Meta-analysis
JAMA, March 2021 ; DOI: 10.1001/jama.2021.2747
 
Garibaldi BT et al
Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19
JAMA, March 2021;  doi:10.1001/jamanetworkopen.2021.3071
 
Olimpieri PP et al
Mortality after remdesivir treatment of pneumonia in hospitalised patients with laboratory confirmed COVID-19: national data in the Italian real-world practice collected by the AIFA
 
Grieco DL et al
Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure The HENIVOT Randomized Clinical Trial
JAMA, March 2021; doi:10.1001/jama.2021.4682
 
Jimenez-Soto R et al
The impact of different prophylactic anticoagulation doses on the outcomes of patients with COVID-19
Thrombosis Research, November 2020 ; doi.org/10.1182/blood-2020-142594
 
Yuan S et al
Clofazimine broadly inhibits coronaviruses including SARS-CoV-2
 
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit The INSPIRATION Randomized Clinical Trial
JAMA, March 2021; doi:10.1001/jama.2021.4152
 
Al-Samkari H et al
Finding the Optimal Thromboprophylaxis Dose in Patients With COVID-19
JAMA, March 2021; doi:10.1001/jama.2021.4295
 
Geurts MH et al
The Organoid Platform: Promises and Challenges as Tools in the Fight against COVID-19
Stem Cell Reports, March 2021; doi.org/10.1016/j.stemcr.2020.11.009
 
Kyriazopoulou E et al
An open label trial of anakinra to prevent respiratory failure in COVID-19
eLife ; March 2021 ; DOI: 10.7554/eLife.66125
 
Ramakrishnan S et al
Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial
medRXiv – not peer reviewed, February 2021;
 
ACTIV-3/TICO LY-CoV555 Study Group
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
NEJM, December 2020; DOI: 10.1056/NEJMoa2033130
 
Touafchia A et al
Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns
Clinical Microbiology and Infection, February 2021; doi.org/10.1016/j.cmi.2021.02.013
 
Kalil AC et al
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
NEJM, March 2021 ; DOI: 10.1056/NEJMoa2031994
 
López-Medina E et al
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial
JAMA, March 2021;  doi:10.1001/jama.2021.3071
 
Hill A et al
Preliminary meta-analysis of randomized trials of ivermectin to treat SARSCoV-2 infection
ResearchSquare – not peer reviewed, January; DOI:10.21203/rs.3.rs-148845/v1
 
Ma S et al
Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials
Nature, February 2021;  DOI: 10.1038/s41392-021-00521-7
 
Khan F et al
Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19
Thorax, February 2021; doi: 10.1136/thoraxjnl-2020-215266
 
Al- Samkari H et al
Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19
Annals of Internal Medicine, January 2021; DOI: 10.7326/m20-6739 
 
Patell R et al
Pharmacologic Thromboprophylaxis and Thrombosis in Hospitalized Patients with COVID-19: A Pooled Analysis
Thrombosis and Haemosthasis, December 2020;  DOI: 10.1055/s-0040-1721664
 
Rentsch CT et al
Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study
The BMJ, February 2021; doi.org/10.1136/bmj.n311 
 
Libster R et al
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
NEJM, February 2021; DOI: 10.1056/NEJMoa2033700
 
Simonovich VA et al                                                                                                    
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
NEJM, February 2021; DOI: 10.1056/NEJMoa2031304
 
Alhazzani W et al
Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update
Critical Care Medicine, February 2021; doi: 10.1097/CCM.0000000000004899
 
Feld JJ et al
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial
The Lancet, February 2021; doi.org/10.1016/S2213-2600(20)30566-X
 
Prud’homme E et al
Effect of Prone Positioning on the respiratory support of non-intubated patients with COVID-19 and acute hypoxemic respiratory failure: A retrospective matching cohortstudy
Chest, January 2021 ; DOI: 10.1016/j.chest.2021.01.048
 
Chapman J et al
CNS Complications in Adult Patients Treated With Extracorporeal Membrane Oxygenation
Critical Care Medicine, February 2021 ; DOI: 10.1097/CCM.0000000000004789
 
Kaka AS et al
Major Update: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points
Annals of Internal Medicine, February 2021; doi.org/10.7326/M20-5752
 
Ammassari A et al
Comparison of Demand for Drugs Used for COVID-19 Treatment and Other Drugs
During the Early Phase of the COVID-19 Pandemic in Italy
JAMA Open, Febraury 2021; doi:10.1001/jamanetworkopen.2020.37060
 
WHO Solidarity Trial Consortium
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
NEJM,  Febraury 2021; DOI: 10.1056/NEJMoa2023184
 
Lacout A et al
Hydroxychloroquine in Hospitalized Patients with Covid-19
NEJM , February 2021 ; DOI: 10.1056/NEJMc2035374
 
Fiolet T et al
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis
Clinical Microbiology and Infection, 1 January 2021 ; doi.org/10.1016/j.cmi.2020.08.022
 
Paul M et al
Has the door closed on hydroxychloroquine for SARS-COV-2?
Clinical Microbiology and Infection, 19 October 2020; doi.org/10.1016/j.cmi.2020.10.011
 
Raoult D et al
Rational for meta-analysis and randomized treatment: the COVID-19 example
Clinical Microbiology and Infection, 21 October 2020; doi.org/10.1016/j.cmi.2020.10.012
 
Leibovici L
Difficult editorial decisions
Clinical Microbiology and Infection, 27 January 2021; DOI: 10.1016/j.cmi.2020.10.013
 
Zheng R et al
COVID-19-associated coagulopathy: thromboembolism prophylaxis and poor prognosis in ICU
BMCExperimental Hematology & Oncology, 01 Febrary 2021; doi.org/10.1186/s40164-021-00202-9
 
Mitjà O et al
A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19
NEJM, 4 Febrary 2021; DOI: 10.1056/NEJMoa2021801
 
Starr TN et al
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Science, 1 December 2020; doi.org/10.1101/2020.11.30.405472
 
Thomson EC et al
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
Cell, 22 January 2021; doi: 10.1016/j.cell.2021.01.037
 
Chaccour C et al
The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial
EClinicalMedicine, 19 January 2021 ; doi.org/10.1016/j.eclinm.2020.100720
 
Schjorring OL et al
Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure
NEJM, 20 January 2021; DOI: 10.1056/NEJMoa2032510
 
Weinreich DM et al
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
NEJM, 21 January 2021 ; DOI: 10.1056/NEJMoa2035002
 
Morgan C et al
Almitrine Infusion in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Acute Respiratory Distress Syndrome: A Single-Center Observational Study
Critacl Care medicine, February 2021 - Volume 49 - Issue 2 - p e191-e198; doi: 10.1097/CCM.0000000000004711
 
Joyner MJ et al
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
NEJM, 13 January 2021 ; DOI: 10.1056/NEJMoa2031893
 
COVID -19/HIV-AIDS
 
Lee MJ et al
Clinical outcomes of patients with and without HIV hospitalized with COVID- 19 in England during the early stages of the pandemic: a matched retrospective multi- centre analysis (RECEDE- C19 study)
 
Melanie Stecher M. et al.
Treatment modifcation after starting cART in people living with HIV: retrospective analysis of the German ClinSurv. HIV Cohort 2005–2017
Infection, July 2020; doi.org/10.1007/s15010-020-01469-6
 
Nachega SB et al
Scaling Up Covid-19 Vaccination in Africa — Lessons from the HIV Pandemic
NEJM, July 2021;  DOI: 10.1056/NEJMp2103313
 
Shinde V et al
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
NEJM, May 2021 ; DOI: 10.1056/NEJMoa2103055
 
Stanford KA et al
Incorporating HIV Screening With COVID-19 Testing in an Urban Emergency Department During the Pandemic
JAMA, April 2021;  doi:10.1001/jamainternmed.2021.0839
 
Laracy J et al
HIV-1 Infection Does Not Change Disease Course or Inflammatory Pattern of SARS-CoV-2-Infected Patients Presenting at a Large Urban Medical Center in New York City
Open Forum Infectious Diseases, February 2021; doi.org/10.1093/ofid/ofab029
 
Tesoriero JM et al
COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State
JAMA, Febrary 2021; DOI: 10.1001/jamanetworkopen.2020.37069
 
Ceballos ME et al
Clinical characteristics and outcomes of people living with HIV hospitalized with COVID-19: a nationwide experience
International Journal of STD & AIDS, Febrary 2021; DOI: 10.1177/0956462420973106
 

VACCINES

Elie Dolgin
Omicron is supercharging the COVID vaccine booster debate
 
Clinical Infectious Diseases
Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons with Breakthrough SARS-CoV-2 Infection in a High-risk National Population
 
Gillot C et al.
Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects
 
Rosemberg E.S. et al.
Covid-19 Vaccine Effectiveness in New York State
 
Munro A.P.S. et al.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
 
Tenforde MW et al.
Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity
 
Mizrai B et al.
Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
                           
Toledo-Romani M.E. et al.
Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination
 
Tenforde M.W. et al.
Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity
 
Burckhardt RM, et al.
Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters
 
Bosch W et al.
COVID-19 Vaccine-Breakthrough Infections Requiring Hospitalization in Mayo Clinic Florida through August 2021
 
Naam Barda et al.
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
 
Lucas C. et al.
Nature, Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
 
Shachor-Meyouhas Y. et al.
Single BNT162b2 vaccine dose produces seroconversionin under 60 s cohort
Vaccine,
 
Tenforde MW et al
Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity
 
North MC et al.
Determining the Incidence of Asymptomatic SARS-CoV-2 Among Early Recipients of COVID-19 Vaccines (DISCOVER-COVID-19): A Prospective Cohort Study of Healthcare Workers Before, During and After Vaccination
 
Andreano E. et al.
Hybrid immunity improves B cells and. antibodies against SARS-CoV-2 variants
 
Glockner S.
Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection
 
Siddle K. J. et al.
Evidence of transmission from fully vaccinated individuals in a large outbreak of the SARS-CoV-2 Delta variant in Provincetown, Massachusetts
 
Collier A. Y. et al
Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts
 
Goel R. R. et al
mRNA vaccines induce durable immune memory to  SARS-CoV-2 and variants of concern
 
Casadevall A.
The mRNA vaccine revolution is the dividend from decades of basic science research
The Journal of Clinical Investigation, https://www.jci.org/articles/view/153721/pdf
 
Jeong Seri et al.
Comparing Results of Five SARS-CoV-2 Antibody Assays Beforeand After the First Dose of ChAdOx1 nCoV-19 Vaccine amongHealth Care Workers
 
Chekuri S et al
SARS-CoV-2 coinfection with additional respiratory virus does not predict severe disease: a retrospective cohort study
Journal of Antimicrobial Chemotherapy,
 
Van Praet JT, et al.
Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents.
 
Mateus J. et al.
Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
 
Bar-On Y. M. et al
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
 
Shah ASV et al.
Effect of Vaccination on Transmission of SARS-CoV-2
 
Wu S et al
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial
 
COVID vaccines have higher approval in less-affluent countries
Nature news, July 2021; doi.org/10.1038/d41586-021-01987-9
 
Stumpf J et al
Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine
The Lancet, July 2021; DOI: 10.1016/j.lanepe.2021.100178
 
Shotri M et al
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
The Lancet, July 2021 ; doi.org/10.1016/S0140-6736(21)01642-1
 
Thomas SJ et al
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
MedRXiv, July 2021; doi.org/10.1101/2021.07.28.21261159
 
Abbasi J
Überantibodies From Recovered COVID-19 Patients Could Spur New Therapeutics and Vaccines
JAMA, July 2021;  doi:10.1001/jama.2021.12915
 
Yang S et al
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
The Lancet, March 2021; doi: 10.1016/S1473-3099(21)00127-4
 
Mendonca Guimaraes R et al
Younger Brazilians hit by COVID-19 – What are the implications?
The Lancet, July 2021 ; doi.org/10.1016/j.lana.2021.100014
 
Woolf K et al
Ethnic differences in SARS-CoV-2 vaccine hesitancy in United Kingdom healthcare workers: Results from the UK-REACH prospective nationwide cohort study
The Lancet, July 2021; DOI: 10.1016/j.lanepe.2021.100180
 
Lim WW et al
Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
 
Butt AA et al
SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting
Annals of Internal Medicine, July 2021; DOI: 10.7326/M21-1577
 
Brosh-Nissimov T et al
BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel
CMI, July 2021 ; DOI: 10.1016/j.cmi.2021.06.036
 
Souza WM et al
Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study
The Lancet, July 2021 ; doi.org/10.1016/S2666-5247(21)00129-4
 
Reynolds CJ et al
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
Science, April 2021 ; DOI: 10.1126/science.abh1282
 
Goldshtein I et al
Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women
JAMA, July 2021; DOI: 10.1001/jama.2021.11035
 
Rossi AH et al
Sputnik V Vaccine Elicits Seroconversion and Neutralizing Capacity to SARS CoV-2 after a Single Dose
 
Jara A et al
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
NEJM, July 2021 ; DOI: 10.1056/NEJMoa2107715
 
Goldfarb JL et al
Beyond the First Dose — Covid-19 Vaccine Follow-through and Continued Protective Measures
NEJM, July 2021; DOI: 10.1056/NEJMp2104527
 
al Jalali V et al          
Improved immunogenicity against SARS-CoV-2 in a solid organ transplant recipient by switching vaccines
CMI, June 2021; DOI: 10.1016/j.cmi.2021.06.022 
 
Han B et al
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial
 
Lustig Y et al
Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
NEJM, June 2021 ; DOI: 10.1056/NEJMc2104036
 
COVID vaccines and breastfeeding: what the data say
 
Collier DA et al
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
 
Wang Z et al
Vaccination boosts naturally enhanced neutralizing breadth to SARS-CoV-2 one year after infection
bioRXiv – not peer reviewed, May 2021; doi.org/10.1101/2021.05.07.443175
 
Heath PT et al
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
NEJM, June 2021; DOI: 10.1056/NEJMoa2107659
 
Kamar N et al
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
NEJM, June 2021 ; DOI: 10.1056/NEJMc2108861
 
Milman O et al
Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals
 
Bollyky TJ et al
Epidemiology, not geopolitics, should guide COVID-19 vaccine donations
 
Wang Z et al
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
 
Herishanu Y et al
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Blood, June 2021 ;  DOI: 10.1182/blood.2021011568
 
Sax P
We’re Allowed to Say that Some COVID-19 Vaccines Are Better than Others, Right?
HIV and ID Observations –NEJM, https://blogs.jwatch.org/hiv-id-observations/
 
Bourguignon A et al
Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia
NEJM, June 2021 ; DOI: 10.1056/NEJMoa2107051
 
Thakkar A et al
Seroconversion rates following COVID-19 vaccination amongst patients with cancer
Cancer Cell, June 2021;  DOI: 10.1016/j.ccell.2021.06.002
 
Istituto Superiore di Sanità
Impatto della vaccinazione COVID-19 sul rischio di infezione da SARS-CoV-2 e successivo ricovero e decesso in Italia (27.12.2020 - 03.05.2021)
 
Takuva S et al
Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study
NEJM, June 2021; DOI: 10.1056/NEJMc2107920
 
Harrington P et al
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
 
Hodgson D et al
The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant
Eurosurveillance, May 2021 ;  DOI: 10.2807/1560-7917.ES.2021.26.20.2100428
 
Bboum Y et al
Africa needs local solutions to face the COVID-19 pandemic
The Lancet, March 2021 ; doi.org/10.1016/S0140-6736(21)00719-4
 
Nawal AK et al
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial
JAMA, May 2021; doi:10.1001/jama.2021.8565
 
Wallace M et al
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021
 
Roeker LE et al
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia
 
Shinde V et al
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
NEJM, May 2021; DOI: 10.1056/NEJMoa2103055
 
Saunders KO et al
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
 
Johnston MS et al
Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine
A Case Series
JAMA ; May 2021 ; doi:10.1001/jamadermatol.2021.1214
 
Reynolds CJ et al
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
Science, April 2021 ; DOI: 10.1126/science.abh1282
 
Fabiani M et al
Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021 separator commenting unavailable
Eurosurveillance , April 2021, doi.org/10.2807/1560-7917.ES.2021.26.17.2100420
 
Boyarski BJ et al
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
JAMA, May 2021 ; doi:10.1001/jama.2021.7489
 
Shinde V et al
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
NEJM, May 2021 ; DOI: 10.1056/NEJMoa2103055
 
Butt AA et al
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
NEJM, May 2021; DOI: 10.1056/NEJMc2104974
 
Menni C et al
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
 
Paul Sax
The decision on the Johnson and Johnson COVID-19 vaccine surprised me, here’s why
HIV and ID Observations – NEJM,
 
Chappell KJ et al
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial
 
EuropeanMedicines Agency
COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
 
Taquet M et al
Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine
 
Gresele P et al
Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET)
Blood transfusion, April 2021; DOI 10.2450/2021.0117-21
 
Sadoff J et al
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
NEJM, April 2021;  DOI: 10.1056/NEJMoa2101544
 
Mmarks P
Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine
 
European Medicines Agency
COVID-19 Vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues
 
Anichini G et al
SARS-CoV-2 Antibody Response in Persons with Past Natural Infection
NEJM, April 2021; DOI: 10.1056/NEJMc2103825
 
Dagan N et al
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
NEJM, April 2021; DOI: 10.1056/NEJMoa2101765
 
Muir K et al
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination
NEJM, April 2021; DOI: 10.1056/NEJMc2106075
 
Jentsch PC et al
Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study
 
The Lancet Microbe Editorial Board
Vaccine certificates: does the end justify the means?
 
Wang L et al
Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization
NEJM, April 2021; DOI: 10.1056/NEJMc2103022
 
Doria-Rose N et al
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
NEJM, April 2021; DOI: 10.1056/NEJMc2103916
 
EuropeanMedicines Agency
AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
 
Van Praet JT et al
Humoral and cellular immunogenicity of the BNT162b2 mRNA Covid-19 Vaccine in nursing home residents
Clinical Infectious Diseases, April 2021; doi.org/10.1093/cid/ciab300
 
Van Praet JT et al
Humoral and cellular immunogenicity of the BNT162b2 mRNA Covid-19 Vaccine in nursing home residents
Clinical Infectious Diseases, April 2021; doi.org/10.1093/cid/ciab300   
   
Westholter D et al
SARS-CoV-2 outbreak in a long-term care facility after vaccination with BNT162b2
Clinical Infectious Diseases, April 2021; doi.org/10.1093/cid/ciab299
 
Glover RE et al
Vaccinating against covid-19 in people who report allergies
BMJ, January 2021; doi.org/10.1136/bmj.n120 
 
Greinacher A et al
A Prothrombotic Thrombocytopenic Disorder Resembling Heparin-Induced Thrombocytopenia Following Coronavirus-19 Vaccination
Preprint- not peer reviewed, March 2021; DOI: 10.21203/rs.3.rs-362354/v1
 
Gesellschaft für Thrombose- und Hämostaseforschung
Updated GTH statement on vaccination with the AstraZeneca COVID-19vaccine, as of March 22, 2021
 
Kupferschmidt K et al
A rare clotting disorder may cloud the world’s hopes for AstraZeneca’s COVID-19 vaccine
 
Thompson MG et al
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health CarePersonnel, First Responders, and Other Essential and Frontline Workers —Eight U.S. Locations, December 2020–March 2021
 
Stamatato L et al
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
Science, Marchc 2021; DOI: 10.1126/science.abg9175
 
Blumenthal KG et al
Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-C
NEJM, April 2021, DOI: 10.1056/NEJMc2102131
 
Hall MA et al
“Vaccine Passport” Certification — Policy and Ethical Considerations
NEJM, March 2021 ; DOI: 10.1056/NEJMp2104289
 
Meyer MN et al
Trends in Health Care Worker Intentions to Receive a COVID-19 Vaccine and Reasons for Hesitancy
JAMA, March 2021 ; doi:10.1001/jamanetworkopen.2021.5344
 
Sax P
COVID-19 vaccines FAQs: Are there minimum or maximum ages for patients to receive the vaccine?
 
Keehner J et al
SARS-CoV-2 Infection after Vaccination in Health Care Workers in California
NEJM, March 2021 ; DOI: 10.1056/NEJMc2101927
 
Benenson S et al
BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers
NEJM, March 2021 ; DOI: 10.1056/NEJMc2101951
 
The Lancet Infectious Diseases Editorial Board
The COVID-19 exit strategy—why we need to aim low
The Lancet Infectious Diseases, February 2021; DOI: 10.1016/s1473-3099(21)00080-3 
 
Agenzia Italiana del Farmaco
AIFA: sospensione precauzionale del vaccino AstraZeneca
 
European Medicines Agency
Investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events continues Share
 
Medicines & Healthcare products Regulatory Agency – United Kingdom
Coronavirus vaccine - weekly summary of Yellow Card reporting
 
Madhi SA et al
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
NEJM, March 2021; DOI: 10.1056/NEJMoa2102214
 
Boyarsky BJ et al
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
JAMA, March 2021 ; doi:10.1001/jama.2021.4385
 
Krutikov M et al
Spread of a Variant SARS-CoV-2 in Long-Term Care Facilities in England
NEJM, March 2021 ; DOI: 10.1056/NEJMc2035906
 
Luchsinger LL et al
Vaccine efficacy probable against COVID-19 variants
Science, March 2021 ; DOI: 10.1126/science.abg9461
 
European Medicines Agency
COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets
 
Agenzia Italiana del Farmaco
Dopo parere EMA, domani riprendono vaccinazioni con AstraZeneca
 
Paul Erlich Institut
FAQ – Temporary suspension of COVID-19 vaccine AstraZeneca
 
Blumenthal KG et al
Acute Allergic Reactions to mRNA COVID-19 Vaccines
JAMA, March 2021 ; doi:10.1001/jama.2021.3976
 
Capetti AF et al
Impressive boosting of anti-S1/S2 IgG production in COVID-19-experienced patients after the first shot of the BNT162b2 mRNA COVID-19 Vaccine
Clinical Infectious Diseases, March 2021; doi.org/10.1093/cid/ciab214
 
Rapaka RR et al
Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines
Clinical Infectious Diseases, March 2021 ; doi.org/10.1093/cid/ciab213
 
Saad-Roy CM et al
Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
Science, March 2021 ; DOI: 10.1126/science.abg8663
 
Raches E et al
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
The Lancet, March 2021 ; doi.org/10.1016/S1473-3099(21)00070-0
 
The Centers for Disease Control and Prevention
Guidance for Fully Vaccinated People
 
Christie A et al
CDC Interim Recommendations for Fully Vaccinated People An Important First Step
JAMA, March 2021 ; doi:10.1001/jama.2021.4367
 
Stephenson KE et al
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
JAMA, March 2021 ; doi:10.1001/jama.2021.3645
 
Rinott E et al
Reduction in COVID-19 patients requiring mechanical ventilation following implementation of a national COVID-19 vaccination program – Israel, December 2020-February 2021
Morbidity and Mortality Weekly Report, https://www.cdc.gov/mmwr/volumes/70/wr/mm7009e3.htm
 
Public Health England
New data show vaccines reduce severe COVID-19 in older adults
 
Bernal JL et al
Early effectiveness of COVID-19 vaccination with vBNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in the UK: a test negative case control study
Preprint, not peer- reviewed, March 2021; DOI: 10.1101/2021.03.01.21252652 
 
Saadat S et al
Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2
JAMA, March 2021 ; doi:10.1001/jama.2021.3341
 
Mainsty C et al
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
The Lancet, February 2021; doi.org/10.1016/S0140-6736(21)00501-8
 
Ooliver SE et al
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen  COVID-19 Vaccine
Morbidity and Mortality Weekly Report, https://www.cdc.gov/mmwr/volumes/70/wr/mm7009e4.htm
 
Blumenthal KG et al
Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
NEJM, March 2021 ; DOI: 10.1056/NEJMc2102131
 
Pasin L et al
Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies
European Journal of Internal Medicine, February 2021; doi.org/10.1016/j.ejim.2021.01.016
 
FDA Briefing Document
Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19
 
Dagan N et al
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
NEJM, February 2021 ; DOI: 10.1056/NEJMoa2101765
 
Katz MH et al
How to Advise Persons Who Are Antibody Positive for SARS-CoV-2 About Future Infection Risk
JAMA, February 2021 ;  doi:10.1001/jamainternmed.2021.0374
 
Hodgson SH et al                                                                                                                                         
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
The Lancet, October 2020; doi.org/10.1016/S1473-3099(20)30773-8
 
Wu K et al                                               
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report
NEJM, February 2021; DOI: 10.1056/NEJMc2102179
 
Voysey M et al
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
The Lancet, February 2021; doi.org/10.1016/S0140-6736(21)00432-3
 
Kadire SR et al
Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination
NEJM, February 2021; DOI: 10.1056/NEJMclde2101987
 
Amit S et al
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
The Lancet, February 2021; doi.org/10.1016/ S0140-6736(21)00448-7
 
Olliaro P
What does 95% COVID-19 vaccine efficacy really mean?
The Lancet, February 2021; doi.org/10.1016/S1473-3099(21)00075-X
 
Mallapaty S
Can COVID vaccines stop transmission? Scientists race to find answers
Nature, February 2021; doi.org/10.1038/d41586-021-00450-z
 
Robertson JFR et al
Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
The Lancet, February 2021; doi.org/10.1016/ S0140-6736(21)00455-4
 
Pfizer.com/ News
Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA
 
Amit S et al
Post-Vaccination COVID-19 among Healthcare Workers, Israel
Emerging Infectious Diseases, Febraury 2021; https://doi.org/10.3201/eid2704.210016
 
Xie X et al
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
Nature, February 2021 ; doi.org/10.1038/s41591-021-01270-4
 
University of Oxford
ChAdOx1 nCov-19 provides minimal protection against mild-moderate COVID-19 infection from B.1.351 coronavirus variant in young South African adults
 
Logunov DY et al
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
The Lancet, February 2021 ; doi.org/10.1016/S0140-6736(21)00234-8
 
Krammer F et al
Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine
medRXiv – not peer reviewed, February 2021; doi.org/10.1101/2021.01.29.21250653
 
Mahase E et al
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant
BMJ, February 2021;  doi: https://doi.org/10.1136/bmj.n296
 
Baden LR et al
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
NEJM, February 2021; DOI: 10.1056/NEJMoa2035389
 
Rappuoli R et al
Vaccinology in the post−COVID-19 era
Proceedings of the National Academy of Sciences, January 2021;
 
Muik A et al
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera
bioRXiv – not peer reviewed, January 2021; doi.org/10.1101/2021.01.18.426984
 
Wu K et al
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
bioRXiv– not peer reviewed, January 2021; doi.org/10.1101/2021.01.25.427948.
 
Mahase E
Covid-19: What new variants are emerging and how are they being investigated?
BMJ, January 2021; doi.org/10.1136/bmj.n158
 
Connors M et al
SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn
Annals of Internal Medicine, 19 January 2021; doi.org/10.7326/M21-0111
 
Klass P et al
Vaccinating Children against Covid-19 — The Lessons of Measles
NEJM, 20 January 2021; DOI: 10.1056/NEJMp2034765
 
Greaney AJ et al
Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies
BioRXiv, 4 January 2021; doi.org/10.1101/2020.12.31.425021Sadoff J et al
 
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
NEJM, 13 January 2021 ; doi: 10.1056/NEJMoa2034201
 
Pollard A et al
How the Oxford-AstraZeneca covid-19 vaccine was made
BMJ, 12 January 2021 ; doi.org/10.1136/bmj.n86
 
Topol EJ et al
Messenger RNA vaccines against SARS-CoV-2
Cell, 13 January 2021 ; doi.org/10.1016/j.cell.2020.12.039
 
CO INFECTIONS – SUPER INFECTIONS
 
Nabity SA et al.
Sociodemographic Characteristics, Comorbidities, and Mortality Among Persons Diagnosed With Tuberculosis and COVID-19 in Close Succession in California, 2020
 
Priscilla KBA et al.
Duration of SARS-CoV-2 Natural Immunity and Protection against the Delta Variant: A Retrospective Cohort Study
CID,
 
Janssen NAF et al.
Multinational Observational Cohort Study of COVID-19–Associated Pulmonary Aspergillosis
 
Achan J et al.
Current malaria infection, previous malaria exposure, and clinical profiles and outcomes of COVID-19 in a setting of high malaria transmission: an exploratory cohort study in Uganda
The Lancet Microbe,
 
Prattes J et al.
Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry
 
Zhu N et al.
Changing patterns of bloodstream infections in the community and acute care across two COVID-19 epidemic waves: a retrospective analysis using data linkage
Clinical Infectious Diseases,
 
Mina Fazel et al.
Willingness of children and adolescents to have a COVID-19 vaccination: Results of a large whole schools survey in England
EClinicalMedicine,
 
Lyndsey D. Cole, MD
IVIG Compared to IVIG Plus Infliximab in Multisystem
Inflammatory Syndrome in Children
 
A.Tagarro et al.
Dynamics of RT-PCR and Serologic Test Results in Children with SARS-CoV-2 Infection
The Journal of Pediatrics,
 
David A. Siegel et al.
Morbidity and Mortality Weekly Report
Trends in COVID-19 Cases, Emergency Department Visits, and Hospital Admissions Among Children and Adolescents Aged 0–17 Years — United States, August 2020–August 2021
Morbidity and Mortality Weekly Report,
 
Wang, Ji-Gan et al.
Computed tomography features of COVID-19 in children: A systematic review and meta-analysis.
Medicine (Baltimore),
 
M. Etti et al.
Global research priorities for COVID-19 in maternal, reproductive and child health
 
ShengLi Xia et al
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial
The Lancet, https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2901908-5https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2901908-5
 
Bernadette C Young et al.
Daily testing for contacts of individuals with SARS-CoV-2 infection and attendance and SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, cluster-randomised trial
The Lancet, https://doi.org/10.1016/S0140-6736(21)01908-5
 
Ankita G Sharma et al
Predictors of mortality in children admitted with SARS-CoV-2 infection in tertiary care hospital in North India
Journal of Paediatrics and Child Health,
 
The Association Between School Closures and Child Mental Health During COVID-19
 
Alon Geva et al.
Data-driven clustering identifies features distinguishing multisystem inflammatory syndrome from acute COVID-19 in children and adolescents
 
Fekkar A et al
COVID-19 associated pulmonary aspergillosis (CAPA): how big a problem is it?
CMI, June 2021 ; DOI: 10.1016/j.cmi.2021.06.025
 
Rabagliati R et al
COVID-19–Associated Mold Infection in Critically Ill Patients, Chile
Emerging Infectious Diseases, March 2021; DOI: 10.3201/eid2705.204412
 
Petrone L et al
Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2
International Journal of Infectious Diseases, March 2021; DOI: 10.1016/j.ijid.2021.02.090
 
Versyck M et al
Invasive pulmonary aspergillosis in COVID-19 critically ill patients: Results of a French monocentric cohort
Journal of Mycology and Medicine, February 2021; DOI: 10.1016/j.mycmed.2021.101122
 
Cusumano JC et al
Staphylococcus aureus Bacteremia in Patients Infected With COVID-19: A Case Series
Open Forum Infectious Diseases, 11 November 2020; doi.org/10.1093/ofid/ofaa518
 
Giacobbe DR et al
Bloodstream infections in critically ill patients with COVID-19
European Journal of Clinical Investigation, 14 June 2020; doi.org/10.1111/eci.13319
 
News From the Centers for Disease Control and Prevention              
Drug-Resistant Bacteria Outbreak Linked to COVID-19 Patient Surge
JAMA,  26 January 2021;  doi:10.1001/jama.2020.26113
 
Marr KA et al
Aspergillosis Complicating Severe Coronavirus Disease
Emerging Infectious Diseases, Volume 27, Number 1—January 2021; DOI: 10.3201/eid2701.202896
 
Maes M et al
Ventilator-associated pneumonia in critically ill patients with COVID-19
Critical Care, 11 January 2021 ; doi.org/10.1186/s13054-021-03460-5
 
Marr KA et al
Aspergillosis Complicating Severe Coronavirus Disease
Emerging Infectious Diseases, Volume 27, Number 1—January 2021; DOI: 10.3201/eid2701.202896
 
PEDIATRICS AND PREGNANCY
 
Walter E.B. et al.
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
 
JAMA Pediatr.,
 
McDaniel, Charles Griffin et al.                                                         
Coagulation Abnormalities and Clinical Complications in Children With SARS-CoV-2: A Systematic Review of 48,322 Patients
Journal of Pediatric Hematology/Oncology,
 
Robin Kahn et al.
Population- based study of multisystem inflammatory syndrome associated with COVID- 19 found that 36% of children had persistent symptoms
 
Lorena Acevedo et al.
Mortality and clinical characteristics of multisystem inflammatory syndrome in children (MIS-C) associated with covid-19 in critically ill patients: an observational multicenter study (MISCO study)
BMC Pediatrics,
 
Hari Krishnan Kanthimathinathan et al.
In the eye of the storm: impact of COVID-19 pandemic on admission patterns to paediatric intensive care units in the UK and Eire
Critical Care,
 
Juliane Schneider et al.
The Role of Face Masks in the Recognition of Emotions by Preschool Children
JAMA Pediatr,
 
Supriya S. Jain et al.
COVID-19 Vaccination–Associated Myocarditis in Adolescents
 
Dolores Sabina Romero Ramírez et al.
SARS-CoV-2 Antibodies in Breast Milk After Vaccination
 
Maria Giulia Conti et al.
Immune Response of Neonates Born to Mothers Infected With SARS-CoV-2
 
Eirini Kostopoulou et al.
The impact of COVID-19 on paediatric emergency department visits. A one-year retrospective study
 
Atyeo C, et al.
COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women
 
Constanze Heinzel et al.
Non-Invasive Antibody Assessment in Saliva to Determine SARS-CoV-2 Exposure in Young Children
 
Zeynep Ertem et al.
The impact of school opening model on SARS-CoV-2 community incidence and mortality
 
Qianling Shi et al.
EClinicalMedicine
Risk factors for poor prognosis in children and adolescents with COVID-19: A systematic review and meta-analysis
 
Jianbo Shao et al.
Factors associated with the time to return negative RT-PCR from COVID-19 in paediatric patients: a retrospective cohort study
 
 Lael M Yonker et al.
Virologic features of SARS-CoV-2 infection in children
 
Rebecca C. Woodruff et al.
Risk Factors for Severe COVID-19 in Children
 
Ulrike Ravens-Sieberer et al.
Quality of life and mental health in children and adolescents during the first year of the COVID-19 pandemic: results of a two-wave nationwide population-based study
European Child & Adolescent Psychiatry, https://link.springer.com/content/pdf/10.1007/s00787-021-01889-1.pdf   
 
Alana K. Otto et al.
Medical Admissions Among Adolescents With Eating Disorders During the COVID-19 Pandemic
 
Musa SS., et al.
Vertical Transmission of SARS-CoV-2: A Systematic Review of Systematic Reviews
 
Kanecia O Zimmerman et al.
Community SARS-CoV-2 Surge and Within-School Transmission
 
Pooja S. Tandon et al.
Association of Children’s Physical Activity and Screen Time With Mental Health During the COVID-19 Pandemic
 
Eveline Y Wu et al
Current Cardiology Reports
Cardiac Manifestations of Multisystem Inflammatory Syndrome in Children (MIS‑C) Following COVID‑19
 
James W Antoon et al.
Factors Associated With COVID-19 Disease Severity in US Children and Adolescents
 
C. Branquinho et al.
COVID‑19 Pandemic and the Second Lockdown: The 3rd Wave of the Disease Through the Voice of Youth
 
Lund LC et al.
Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study
Lancet Infectious Diseases, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00211-5/fulltext
 
Xue Zhang BS et al.
Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, China
 
Martillo MA et al
Postintensive Care Syndrome in Survivors of Critical Illness Related to Coronavirus Disease 2019: Cohort Study From a New York City Critical Care Recovery Clinic
 
Siddiqui S et al
Pathological disease in the lung periphery after acute COVID-19
The Lancet Respiratory Medicine, https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00378-7/fulltext
 
Golan Y et al
Evaluation of Messenger RNA From COVID-19 BTN162b2 and mRNA-1273 Vaccines in Human Milk
JAMA, July 2021 ; DOI: 10.1001/jamapediatrics.2021.1929
 
Buonsenso D et al
Children and SARS-CoV-2 transmission: a step closer to better understanding and evidence-based interventions?
CID, Jube 2021; DOI: 10.1093/cid/ciab559
 
Ministero della Salute isrealiano
The Ministry of Health Recommends Having Teens 12-15 Years of Age Vaccinated
Comunicato stampa
 
McArdle A et al
Treatment of Multisystem Inflammatory Syndrome in Children
NEJM, June 2021; DOI: 10.1056/NEJMoa2102968
 
Son MBF et al
Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes
NEJM, June 2021 ; DOI: 10.1056/NEJMoa2102605
 
Shimabukuro TT et al
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons
NEJM, April 2021 ; DOI: 10.1056/NEJMoa2104983
 
Thompson LA et al
Children and COVID-19 Vaccines
JAMA, April 2021 ; doi: 10.1097/INF.0000000000003042
 
Kompaniyets L et al
Underlying Medical Conditions Associated With Severe COVID-19 Illness Among Children
JAMA, June 2021; doi:10.1001/jamanetworkopen.2021.11182
 
Stepehnson J et al
Children and Teens Struggling with Mental Health During COVID-19 Pandemic
JAMA, June 2021; doi:10.1001/jamahealthforum.2021.1701
 
Wang EW et al
SARS-CoV-2 Vaccination During Pregnancy: A Complex Decision
Open Forum Infectious Diseases, May 2021; doi.org/10.1093/ofid/ofab180
 
Norman M et al
Association of Maternal SARS-CoV-2 Infection in Pregnancy With Neonatal Outcomes
JAMA, April 2021 ; doi:10.1001/jama.2021.5775
 
Bellon M et al
SARS-CoV-2 viral load kinetics in symptomatic children, adolescents and adults
Clinical Infectious Diseases, May 2021; doi.org/10.1093/cid/ciab396
 
Shimabukuro TT et al
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons
NEJM, April 2021 ; DOI: 10.1056/NEJMoa2104983
 
Perl SH et al
SARS-CoV-2–Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women
JAMA, April 2021;  doi:10.1001/jama.2021.5782
 
Gray KJ et al
COVID-19 vaccine response in pregnant and lactating women: a cohort study
American Journal of Obstetrics and Gynecology, March 2021; doi.org/10.1016/j.ajog.2021.03.023
 
Sermet-Gaudelus I et al
Prior infection by seasonal coronaviruses, as assessed by serology, does not prevent SARS-CoV-2 infection and disease in children, France, April to June 2020
 
Lazzerini M et al
Characteristics and risk factors for SARS-CoV-2 in children tested in the early phase of the pandemic: a cross-sectional study, Italy, 23 February to 24 May 2020
 
Niño-Taravilla C et al
Multisystem Inflammatory Syndrome in Children, Chile, May–August 2020
Emerging Infectious Diseases, March 2021; DOI: 10.3201/eid2705.204591
 
Yang HS et al
Association of Age With SARS-CoV-2 Antibody Response
JAMA, March 2021 ; doi:10.1001/jamanetworkopen.2021.4302
 
Soriano – Arandes A et al
Household SARS-CoV-2 transmission and children: a network prospective study
Clinical Infectious Diseases, March 2021 ; DOI: 10.1093/cid/ciab228
 
Jordan I et al
Transmission of SARS-CoV-2 infection among children in summer schools applying stringent control measures in Barcelona, Spain
Clinical Infectious Diseases, March 2021 ; DOI: 10.1093/cid/ciab227
 
Ladhani SN et al
SARS-CoV-2 infection and transmission in primary schools in England in June–December, 2020 (sKIDs): an active, prospective surveillance study
 
Reffo E et al
Inflammatory syndrome in children associated with COVID-19 complicated by acute myocardial infarction
European Heart Journal, February 2021; DOI: 10.1093/eurheartj/ehab077
 
Rollins N et al
A public health approach for deciding policy on infant feeding and mother–infant contact in the context of COVID-19
 
Feldstein LR et al
Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19
JAMA, February 2021;  doi:10.1001/jama.2021.2091
 
Brookman S et al
Effect of the new SARS-CoV-2 variant B.1.1.7 on children and young people
The Lancet, 10 Febraury 2021; doi.org/10.1016/S2352-4642(21)00030-4
 
Ouldali N et al
Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children
JAMA, 1 Febrary 2021; doi:10.1001/jama.2021.0694
 
Tonshoff B et al
Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany
JAMA Pediatrics, 22 January 2021; 10.1001/jamapediatrics.2021.0001
 
Newlove-Delgato T et al
Child mental health in England before and during the COVID-19 lockdown
The Lancet, 11 January 2021; doi.org/10.1016/S2215-0366(20)30570-8
 

LONG COVID SYNDROME

Fang X et al
Post-sequelae one year after hospital discharge among older COVID-19 patients: a multi-center prospective cohort study
Journal of Infection,
 
Pin Li et al
Factors Associated With Risk of PostdischargeThrombosis in Patients With COVID-19
 
Pinato DJ et al
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study
 
Dudouet P et al
Clinical Microbiology and Infection
Aortic 18F-FDG PET/CT hypermetabolism in patients with long COVID: a retrospective study
Clinical Microbiology and Infection, https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(21)00542-5/pdf
 
Perez-Garcia F et al
Age-Adjusted Endothelial Activation and Stress Index for Coronavirus Disease 2019 at Admission Is a Reliable Predictor for 28-Day Mortality in Hospitalized Patients With Coronavirus Disease 2019
 
Blixt L et al
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients
 
Ullrich A., et al. Robert Koch’s Infectious Disease Surveillance Group.
Impact of the COVID-19 pandemic and associated non-pharmaceuticalinterventions on other notifiable infectious diseases in Germany:An analysis of national surveillance data during week 1-2016—week32-2020
The Lancet Regional Health – Europe,
 
Crook H et al
Long covid—mechanisms, risk factors, and management
BMJ, July 2021 ; doi.org/10.1136/bmj.n1648 
 
Barizien N et al
Clinical characterization of dysautonomia in long COVID-19 patients
Scientific Reports, July 2021 ; doi.org/10.1038/s41598-021-93546-5
 
SeeBle J et al
Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study
CID, July 2021 ; DOI: 10.1093/cid/ciab611
 
Radin JL et al
Assessment of Prolonged Physiological and Behavioral Changes Associated With COVID-19 Infection
JAMA, July 2021; doi:10.1001/jamanetworkopen.2021.15959
 
Burke M et al
Long COVID has exposed medicine's blind-spot
 
De Giorgi V et al
Naturally acquired SARS-CoV-2 immunity persists for up to 11 months following infection
The Journal of Infectious Diseases, June 2021;  DOI: 10.1093/infdis/jiab295
 
Verna EC et al
Factors Associated with Readmission in the US Following Hospitalization with COVID-19
 
Istituto Superiore di Sanità
Prevalenza e distribuzione delle varianti del virus SARS-CoV-2 di interesse per la sanità pubblica in Italia
 
Lund LC et al
Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study
 
Huang L et al
Post-acute conditions of patients with COVID-19 not requiring hospital admission
 
Gautam N et al
Medium-term outcome of severe to critically ill patients with SARS-CoV-2 infection
Clinical Infectious Diseases, April 2021; DOI: 10.1093/cid/ciab341
 
Santhosh L et al
“How I Do It: Rapid Design & Implementation of Post-COVID Clinics”
 
Taquet M et al
6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records
 
Havervall S et al
Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers
JAMA, April 2021; doi:10.1001/jama.2021.5612
 
Nalbandian A et al
Post-acute COVID-19 syndrome
 
The Writing Committee for the COMEBAC Study Group
Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19
JAMA, March 2021; DOI: 10.1001/jama.2021.3331
 
Logue JK et al
Sequelae in Adults at 6 Months After COVID-19 Infection
JAMA, February 2021; doi:10.1001/jamanetworkopen.2021.0830
 
Bellan Mattia et al
Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge
JAMA, January 2021; doi:10.1001/jamanetworkopen.2020.36142
 
Huang C et al
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
The Lancet, January 2021 ; doi.org/10.1016/S0140-6736(20)32656-8
 
Salman D et al
Returning to physical activity after covid-19
BMJ, JANUARY 2021 ; doi.org/10.1136/bmj.m4721
 
Mahase E
Covid-19: Past infection provides 83% protection for five months but may not stop transmission, study finds
BMJ, January 2021; doi.org/10.1136/bmj.n124

 

IMPACT OF COVID ON “OTHER DISEASES” AND VICEVERSA

Grave C, et al.
Myocardial infarction throughout 1 year of the COVID-19 pandemic: French nationwide study of hospitalization rates, prognosis and 90-day mortality rates
Arch Cardiovasc Dis,
 
Liu Y, et al.
Dilemma and solutions of treatment delay in cancer patients during the COVID-19 pandemic: A single-center, prospective survey
 
Ting Shi et al.
The Lancet Respiratory Medicine
Risk of COVID-19 hospital admission among children aged 5–17 years with asthma in Scotland: a national incident cohort study
 
OnCovid Study Group
Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry
 
Horiuchi S, et al.
Immune memory from SARS-CoV-2 infection in hamsters provides variant-independent protection but still allows virus transmission
Science Immunology
 
Causey K et al
Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study
The Lancet, July 2021; DOI: 10.1016/S0140-6736(21)01337-4
 
Patel SY et al
Diabetes Care and Glycemic Control During the COVID-19 Pandemic in the United States
JAMA, July 2021; doi:10.1001/jamainternmed.2021.3047
 
Seagle EE et al
The landscape of candidemia during the COVID-19 pandemic
 
Lepak AJ et al
Association of Changes in Seasonal Respiratory Virus Activity and Ambulatory Antibiotic Prescriptions With the COVID-19 Pandemic
JAMA, June 2021 ; DOI: 10.1001/jamainternmed.2021.2621
 
Solomon MD et al
Changes in Patterns of Hospital Visits for Acute Myocardial Infarction or Ischemic Stroke During COVID-19 Surges
JAMA, June 2021; doi:10.1001/jama.2021.8414
 
Wu CT et al
SARS-CoV-2 infects human pancreatic β-cells and elicits β-cell impairment
Cell Metabolism, May 2021 ; doi.org/10.1016/j.cmet.2021.05.013
 
Bodilsen J et al
Hospital admission and mortality rates for non-covid diseases in Denmark during covid-19 pandemic: nationwide population based cohort study
BMJ, May 2021 ; doi.org/10.1136/bmj.n1135
 
Natori Y et al
When is it Safe to perform Abdominal Transplantation in patients with prior SARS-CoV-2 infection: A Case Series
 
Lei H et al
Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis
 
Salto-Alejandre S et al
Risk factors for unfavorable outcome and impact of early post-transplant infection in solid organ recipients with COVID-19: A prospective multicenter cohort study
PloS One, April 2021 ; doi.org/10.1371/journal.pone.0250796
 
Haffner MR et al
Postoperative In-Hospital Morbidity and Mortality of Patients With COVID-19 Infection Compared With Patients Without COVID-19 Infection
JAMA, April 2021; doi:10.1001/jamanetworkopen.2021.5697
 
Pasquel FJ et al
Characteristics of and Mortality Associated With Diabetic Ketoacidosis Among US Patients Hospitalized With or Without COVID-19
JAMA, March 2021 ; doi:10.1001/jamanetworkopen.2021.1091
 
Huls A et al
Medical vulnerability of individuals with down syndrome to severe COVID-19 – data from the trisomy 21 research society and the UK ISARIC4C survey
EClinicalMedicine – The Lancet, February 2021; doi.org/10.1016/j.eclinm.2021.100769
 
Neuroimmunology Brazilian Study Group Focused on COVID-19 and MS
Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis
Multiple Sclerosis Journal, 2 Febrary 2021; DOI: 10.1177/1352458520978354
 
Servick K
COVID-19 measures also suppress flu—for now
Science, 15 January 2021; DOI: 10.1126/science.371.6526.224
 
Sharma A et al
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
The Lancet, 19 January 2021; doi.org/10.1016/S2352-3026(20)30429-4

RE-INFECTION AND RELAPSE

Kojima N et al
Protective immunity after recovery from SARS-CoV-2 infection
 
Goldberg Y et al.
Waning Immunity after the BNT162b2 Vaccine in Israel
 
Milne G.
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
 
Bergwerk M et al.
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
 
Townsend JP, et al.
Lancet Microbe
The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study
 
Caputo V. et al.
Age and Sex Modulate SARS-CoV-2 Viral Load Kinetics: A Longitudinal Analysis of 1735 Subjects.
 
European Centre for Disease Prevention and Control (ECDC)
Assessing SARS-CoV-2 circulation, variants of concern, non-pharmaceutical interventions and vaccine rollout in the EU/EEA, 16th update.
 
Twohig KA et al.
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study
Lancet Infectious Diseases, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00475-8/fulltext
 
Brinkley-Rubinstein L et al
Breakthrough SARS-CoV-2 Infections in Prison after Vaccination
NEJM, July 2021 ; DOI: 10.1056/NEJMc2108479
 
Rennert L et al
Risk of SARS-CoV-2 reinfection in a university student population
 
The Centers for Disease Control and Prevention MMWR Morb Mortal Wkly Rep
COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021
 
Zhang L et al
Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues
 
Amorim MR et al
Respiratory Viral Shedding in Healthcare Workers Reinfected with SARS-CoV-2, Brazil, 2020
Emerging Infectious Diseases, April 2021; doi.org/10.3201/eid2706.210558
 
Hall VJ et al
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)
 
Klein J et al
Case Study: Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient
medRXiv – not peer reviewed, March 2021;  doi.org/10.1101/2021.03.24.21253992
 
Sheehan MM et al
Reinfection Rates among Patients who Previously Tested Positive for COVID-19: a Retrospective Cohort Study
Clinical Infectious Diseases, March 2021; doi.org/10.1093/cid/ciab234
 
Dan J et al
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunity and Reinfection
Clinical Infectious Diseases, January 2021 ; doi.org/10.1093/cid/ciaa1936
 
Lee JT et al
Clinical and Laboratory Findings in Patients with Potential SARS-CoV-2 Reinfection, May–July 2020
Clinical Infectious Diseases, February 2021; DOI: 10.1093/cid/ciab148
 
Reuken PA et al
Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection
Leukemia, February 2021; doi.org/10.1038/s41375-021-01175-8
 
Lumley SF et al                              
Antibody Status and Incidence of SARS-CoV-2Infection in Health Care Workers
NEJM, 23 December 2020; DOI: 10.1056/NEJMoa2034545
 
Hall V et al
Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020
MedRXiv, 15 January 2021; doi.org/10.1101/2021.01.13.21249642
 
 Vasques Nonaka CK et al
Genomic evidence of a SARS-CoV-2 reinfection case with E484K spikemutation in Brazil
Preprint - not peer reviewed, 6 January 2021;  doi: 10.20944/preprints202101.0132.v1

VARIANTS, IMMUNO-ESCAPE/PHENO DIFFERENCES

Abdullah F., et al.
Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in Tshwane, South Africa
 
Torjesen I. 
Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear
 
Patone M et al
Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study
The Lancet, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00318-2/fulltext?dgcid=raven_jbs_etoc_email
 
Carreño JM,e t al.
Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients
EBioMedicine.
 
Taylor C.A., et al.
Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance — COVID-NET, 14 States, January–August 2021
 
Abu-Raddad LJ, et al.
Severity, criticality, and fatality of the SARS-CoV-2 Beta variant
Clinical Infectious Diseases,
 
Harder T. et al.
Effectiveness of COVID-19 vaccines against SARSCoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021
 
Vöhringer, H. S. et al.
Genomic reconstruction of the SARS-CoV-2 epidemic in England
 
Robilotti E.V., et al.
Clinical and Genomic Characterization of SARS CoV-2 infections in mRNA Vaccinated Health Care Personnel in New York City
 
Nanduri S., et al.
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021
 
Tartof S. Y. et al.
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
 
Tao K. et al.
Nature Review Genetics
The biological and clinical significance of emerging SARS-CoV-2 variants
Nature Review Genetics,
 
Lopez Bernal
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
NEJM, July 2021; DOI: 10.1056/NEJMoa2108891
 
Vasireddy D et al
Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know?
J Clin Med Res, June 2021; DOI: 10.14740/jocmr4518 
 
Bates TA et al
Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples
JAMA, July 2021; DOI: 10.1001/jama.2021.11656
 
Lopez Bernal J et al
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
NEJM, July 2021;  DOI: 10.1056/NEJMoa2108891
 
Lazarevic I et al
Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?
Viruses, June 2021;  DOI: 10.3390/v13071192
 
Gan HH et al
Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Asso-ciated with Increased Transmissibility
JMB, July 2021; DOI: 10.1016/j.jmb.2021.167051
 
Reynolds CJ et al
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
Science, April 2021 ; DOI: 10.1126/science.abh1282
 
Krause P et al
SARS-CoV-2 Variants and Vaccines
NEJM, June 2021 ; DOI: 10.1056/NEJMsr2105280
 
Pascarella S et al
SARS-CoV-2 B.1.617 Indian variants: are electrostatic potential changes responsible for a higher transmission rate?
BioRXiv, june 2021, doi.org/10.1101/2021.06.08.445535
 
Sheikh A et al
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
 
Nyberg T et al
Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis
BMJ, June 2021; doi.org/10.1136/bmj.n1412 
 
Shen X et al
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
NEJM, June 2021; DOI: 10.1056/NEJMc2103740
 
Yuan M et al
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Science, May 2021 ; DOI: 10.1126/science.abh1139
 
Istituto Superiore di Sanità
Prevalenza e distribuzione delle varianti del virus SARS-CoV-2 di interesse per la sanità pubblica in Italia
 
Colson P et al
Spreading of a new SARS-CoV-2 N501Y spike variant in a new lineage
Clinical Microbiology and Infection, May 2021; doi.org/10.1016/j.cmi.2021.05.006
 
Clark SA et al
SARS-CoV-2 evolution in an immunecompromised host reveals shared neutralization escape mechanisms
 
Chodick G et al
The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data
 
Bartolini B
The newly introduced SARS-CoV-2 variant A222V is rapidly spreading in Lazio region, Italy
medRXiv – preprint, November 2020; doi.org/10.1101/2020.11.28.20237016
 
Alpert T et al
Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States
 
Liu Y et al
BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
NEJM, May 2021; DOI: 10.1056/NEJMc2106083       
      
Feder KA et al
Linked Clusters of SARS-CoV-2 Variant B.1.351 — Maryland, January–February 2021
Morbidity and Mortality Weekly Report,
 
Hacisuleyman E et al
Vaccine Breakthrough Infections with SARS-CoV-2 Variants
NEJM, April 2021 ; DOI: 10.1056/NEJMoa2105000
 
Faria NR et al
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Science, April 2021; DOI: 10.1126/science.abh2644
 
Betton M et al
Sera neutralizing activities against SARS-CoV-2 and multiple variants six month after hospitalization for COVID-19
Clinical Infectious Diseases, April 2021; doi.org/10.1093/cid/ciab308
 
Frampton D et al
Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study
 
Ong SWX et al
Lack of detail in population-level data impedes analysis of SARS-CoV-2 variants of concern and clinical outcomes
 
Lustig Y et al
Neutralizing Response against Variantsafter SARS-CoV-2 Infection and One Dose of BNT162b2
NEJM, April 2021; DOI: 10.1056/NEJMc2104036
 
Shen X et al
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
NEJM, April 2021; DOI: 10.1056/NEJMc2103740
 
Cele S et al
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
 
Ufficio Stampa Istituto Superiore di Sanità                                                                                           
Comunicato Stampa N° 20/2021 Covid-19: in Italia la ‘variante inglese’ all’86,7% Il 4,0% dei casi con quella ‘brasiliana’
 
Emary KRW et al
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
 
Abdool Karim SS et al
New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications
NEJM, March 2021; DOI: 10.1056/NEJMc2100362
 
Davies NG et al
Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
 
Wu K et al
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine
NEJM, March 2021; DOI: 10.1056/NEJMc2102179
 
Tse H et al
Emergence of a Severe Acute Respiratory Syndrome Coronavirus 2 virus variant with novel genomic architecture in Hong Kong
Clinical Infectious Diseases, March 2021; doi: 10.1093/cid/ciab198
 
Tegally H et al
Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein
 
Nakamichi K et al
Hospitalization and mortality associated with SARS-CoV-2 viral clades in COVID-19
Scientific Reports, February 2021; doi.org/10.1038/s41598-021-82850-9
 
Nonaka CKV et al
Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil
Emerging Infectious Diseases, February 2021; DOI: 10.3201/eid2705.210191
 
Plante JA et al
The Variant Gambit: COVID’s Next Move
Cell Host and Microbe, March 2021 ; doi.org/10.1016/j.chom.2021.02.020
 
Davies NG et al
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Science, March 2021 ; DOI: 10.1126/science.abg3055
 
Li Q et al
No higher infectivity but immune escape of SARS-CoV-2 501Y.V2 variants
 
New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG)
NERVTAG: Update note on B.1.1.7 severity, 11 February 2021
 
Maggi F et al
Imported SARS-COV-2 Variant P.1 Detected in Traveler Returning from Brazil to Italy
Emerging Infectious Diseases, February 2021; DOI: 10.3201/eid2704.210183
 
Kissler SM et al
Densely sampled viral trajectoriessuggest longer duration of acuteinfection with B.1.1.7 variantrelative to non-B.1.1.7 SARS-CoV-2
Harvard Library – preprint, February 2021; doi.org/10.1101/2021.02.16.21251535
 
Liu Y et al
Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report
NEJM , February 2021; DOI: 10.1056/NEJMc2102017
 
Huang B et al
Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines
BioRXiv, February 2021; doi.org/10.1101/2021.02.01.429069
 
Davies NG et al
Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01
medRXiv – not peer reviewed, February 2021; DOI: 10.1101/2021.02.01.21250959
 
Mallapaty S et al
What’s the risk of dying from a fast-spreading COVID-19 variant?
Nature, Febraury 2021; DOI: 10.1038/d41586-021-00299-2
 
Martin MA et al
Insights from SARS-CoV-2 sequences
Science, January 2021; DOI: 10.1126/science.abf3995
 
Zhang W et al
Emergence of a Novel SARS-CoV-2 Variant in Southern California
JAMA, January 2021 ; doi.org/10.1101/2021.01.18.21249786
 
McCarthy KR et al
Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
Science, Febrary 2021; DOI: 10.1126/science.abf6950
 
INFLUENZA. RSV
 
Bhaskaran, K.; et al.
Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform
 
Sing A. et al.
The Safety profile of COVID-19 vaccinations in the United States
 
Erich P et al.
COVID-19 is not “just another flu”: a real-life comparison of severe COVID-19 and influenza in hospitalized patients in Vienna, Austria
Infection, May 2021; DOI: 10.1007/s15010-021-01610-z
 
Adloch C et al.
Very little influenza in the WHO European Region during the 2020/21 season, weeks 40 2020 to 8 2021
 

ADVERSE EVENTS – VACCINE

Rocco JM et al
Hyperinflammatory syndromes after SARS-CoV-2 mRNA vaccination in individuals with underlying immune dysregulation
Clinical Infectious Diseases, December 2021;  doi.org/10.1093/cid/ciab1024 
 
Dongngan T. Truong et al.
Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults
 
Canas L.S. et al.
Disentangling post-vaccination symptoms from early COVID-19
EClinical Medicine,
 
Hause A.M. et. Al
Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12–September 19, 2021
 
Lavin M et al
Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinico-pathological entity with heterogeneous clinical presentations
British Journal of Hematology, June 2021;  DOI: 10.1111/bjh.17613
 
Sangli S et al
Thrombosis With Thrombocytopenia After the Messenger RNA–1273 Vaccine
Annals of Internal Medicine, June 2021; DOI: 10.7326/L21-0244
 
Patriquin CJ et al
Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia
NEJM, July 2021 ; DOI: 10.1056/NEJMc2109465
 
Montogomery J et al
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
JAMA, June 2021; doi:10.1001/jamacardio.2021.2833
 
Kowarz E et al
“Vaccine-Induced Covid-19 Mimicry” Syndrome: Splice reactions within the SARS-CoV-2 Spike open reading frame result in Spike protein variants that may cause thromboembolic events in patients immunized with vector-based vaccines
Research Square – preprint, May 2021 ; DOI:10.21203/rs.3.rs-558954/v1
 

IMMUNOSUPPRESSION AND VACCINE AUTO Ab, ANTI VIRALS

Wilde H et al
The association between mechanical ventilator compatible bed occupancy and mortality risk in intensive care patients with COVID-19: a national retrospective cohort Study
 
Berges AJ et al
Quantifying Viral Particle Aerosolization Risk During Tracheostomy Surgery and Tracheostomy Care
 
Mahil SK et al
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study
The Lancet, July 2021 ; doi.org/10.1016/S2665-9913(21)00212-5
 

ASPETTI INTENSIVISTICI – TERAPIA INTENSIVE

Estrin-Serlui T, et al.
Putrefaction in the pandemic: a comparative study of the frequency of advanced decomposition change in coronial autopsies since the start of the COVID-19 pandemic
 
Amadéo S, et al.
J Int Med Res.
Suicide in French Polynesia: a retrospective analysis based on medicolegal documents and interview with family
 
Aiello F., et al.
Post-Mortem RT-PCR Assay for SARS-CoV-2 RNA in COVID-19 Patients' Corneal Epithelium, Conjunctival and Nasopharyngeal Swabs
J Clin Med. ,https://www.mdpi.com/2077-0383/10/18/4256/htm September 2021
 
Prajapati, S., et al.
Safety Recommendations for Forensic Laboratory Staff During COVID-19 Pandemic
 
 
ASPETTI MEDICO – LEGALI - AUTOPSIE
 
D. Chertowet al.
SARS-CoV-2 infection and persistence throughout the human body and brain
Research Square, December 2021; doi.org/10.21203/rs.3.rs-1139035/v1
 
Milross L, et al.
Post-mortem lung tissue: the fossil record of the pathophysiology and immunopathology of severe COVID-19
Lancet Respir Med. , https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00408-2/fulltext
 
Di Luise E, et al.
Interim recommendations for the management of forensic investigation during the COVID-19 pandemic: An Italian perspective
 
Duarte-Neto AN,et al.
Rapid Mortality Surveillance of COVID-19 Using Verbal Autopsy
 

MEDICINA PERSONALIZZATA/ DI PRECISIONE

Bonnet B, et al.
Severe COVID-19 is characterized by the co-occurrence of moderate cytokine inflammation and severe monocyte dysregulation
 
Singhal L et al
eARDS: A multi-center validation of an interpretable machine learning algorithm of early onset Acute Respiratory Distress Syndrome (ARDS) among critically ill adults with COVID-19
 

STUDI MODELLISTICI COMPUTAZIONALI E/O MACHINE LEARNING E/O INTELLIGENZA ARTIFICIALE

Elien Colman et al.
Following the science? Views from scientists on government advisory boards during the COVID-19 pandemic: a qualitative interview study in five European countries
 
Musa Abubakar Kana et al.
BMJ Global Hearth
Africa's contribution to the science of the COVID-19/SARS-CoV-2 pandemic
 
Mary A. Shiraef et al.
COVID Border Accountability Project, a hand-coded global database of border closures introduced during 2020
 
Erika Arteaga-Cruz, Juan Cuvi
Thinking outside the modern capitalist logic: health-care systems based in other world views
Lancet Global Health , https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00341-7/fulltext
 

GLOBAL HEALTH – ONE HEALTH

Reinstating universal health coverage on the global agenda Editorial
The Lancet, Published: December 04, 2021DOI:https://doi.org/10.1016/S0140-6736(21)02742-
 
Suerie Moon, Jana Armstrong, Brian Hutler, Ross Upshur, Rachel Katz, Caesar Atuire, Anant Bhan, Ezekiel Emanuel, Ruth Faden, Prakash Ghimire, Dirceu Greco, Calvin WL Ho, Sonali Kochhar, G Owen Schaefer, Ehsan Shamsi-Gooshki, Jerome Amir Singh, Maxwell J Smith, Jonathan Wolff
Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability
The Lancet, Published Online December 10, 2021 https://doi.org/10.1016/ S0140-6736(21)02344-8
 
Hodgins M, et al.
The COVID-19 System Shock Framework: Capturing Health System Innovation During the COVID-19 Pandemic
Int J Health Policy Manag,
 
Rohit Malpani and Alex Maitland
Dose of Reality: How rich countries and pharmaceutical corporations are breaking their vaccine promises
 
A. Maxmen
THE FIGHT TO MANUFACTURE COVID VACCINES IN LOWER-INCOME COUNTRIES
 
G. Sherita et al.
Approaching the COVID-19 Pandemic Response With a Health Equity Lens: A Framework for Academic Health Systems
Academic Medicine,
 
Recalling the universal health coverage vision and equity in the COVID-19 vaccine distribution plan
 
LO Gostin et al.
An International Agreement on Pandemic Prevention and Preparedness
 
 

master logo